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Abstract | Tuhinga Whakarāpopoto 
Obesity is a global epidemic, and is the leading risk factor for heart disease and associated 
morbidities in New Zealand. Furthermore, Māori and Pacific New Zealand populations are up 
to 8 times more likely to develop both conditions. Obesity is characterised by an increase in fat 
(adipose tissue) throughout the body, both viscerally (surrounding organs) and subcutaneously 
(beneath the skin). Epicardial Adipose tissue (EAT) is a form of visceral fat located within the 
heart’s pericardial cavity, meaning EAT and the myocardium, maintain a unique, intimate 
relationship. This relationship has highlighted EAT as a possible tool in diagnosing 
cardiovascular disease. Recent studies found that obesity-induced morphological changes to 
EAT are dissimilar to those seen in other subcutaneous or visceral adipose tissues. In obesity, 
while adipocyte size increased in subcutaneous, appendicular and pericardial adipose tissues, 
EAT adipocyte size remained unchanged. Additionally, the well-established increase in overall 
EAT thickness in relation to body mass index (BMI), was not observed in Māori nor Pacific 
New Zealanders. This finding may provide insight into the disproportionate cardiac health 
outcomes for Māori and Pacific peoples in New Zealand. 
  
My study aimed to investigate how obesity effects EAT morphology and cardiac localisation, 
and how these potential changes in EAT might coincide with cardiac remodelling (myocardial 
adipocyte infiltration and fibrosis) and cardiovascular disease prevalence in diverse ethnic 
populations in New Zealand. Additionally, my study aimed to uncover any novel correlations 
between EAT morphology/localisation, cardiac remodelling and anthropomorphic variables 
such as age and sex. I hypothesised that in post mortem cases, NZ/European, but not Māori nor 
Pacific would demonstrate a linear relationship between BMI and mean adipocyte size only in 
non-epicardial adipose tissues (subcutaneous, appendicular and pericardial). Additionally, I 
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hypothesised that Māori and Pacific cases would present with a greater percentage of 
myocardial adipocyte infiltration and fibrosis than their NZ/European, age and BMI matched 
counterparts. 
  
Statistical analysis of adipocyte and left ventricular histology from 91 post mortem cases 
revealed that mean subcutaneous, appendicular and pericardial adipocyte size positively 
correlated with BMI in NZ/European and Māori populations, while not in Pacific populations. 
A significant correlation was identified between the percentage of myocardial adipocyte 
infiltration and mean EAT adipocyte size in Māori/Pacific but not in NZ/European populations. 
Interestingly the opposite was seen in relation to myocardial fibrosis where subcutaneous and 
visceral (appendicular, pericardial, epicardial) adipocyte size significantly correlated with 
myocardial fibrosis in NZ/European, but not Māori/Pacific populations. Lastly, NZ/European 
cases showed a significant correlation between heart weight and BMI, while Māori/Pacific 
cases did not.  
  
In conclusion, the observed differences in adipocyte morphology/localisation between Māori, 
Pacific and NZ/European cases, highlight possible physiological differences, which could 
associate with potential differences in risks factors and disease characteristics between 
populations. My findings question the efficacy of current methods for diagnosis and treatment 
of heart disease and obesity, in all New Zealanders. My research illuminates the unconscious 
bias present in New Zealand healthcare, and highlights the need for more Māori led initiatives 
in both research and clinical practice, to facilitate the provision of equitable healthcare for all. 
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Chapter 1 | Ūpoko Tuatahi 







1.1 Obesity  
Obesity has been well established as one of the most alarming and expansive health crises 
globally (Friedrich, 2017). Worryingly, while the risks and negative health impacts of obesity 
are generally well known, epidemiological data still demonstrates an ever-increasing 
prevalence of obesity globally (Chooi et al., 2019; World Health Organisation, 2020), affecting 
people of all ages, genders and ethnicities. Nearly one-third of the world’s population are now 
classified as overweight or obese (Chooi et al., 2019). Even more alarming is the three-fold 
increase in obesity prevalence observed in recent decades in adolescents and children globally, 
specifically in New Zealand 1 in 10 children are now classed as obese (Chiavaroli et al., 2019; 
Health, 2019). The classifications of obese or overweight, by the World Health Organisation 
(WHO) are based on an individual’s Body Mass Index (BMI)(World Health Organisation, 
2020), which takes into account and individual’s height and body weight. Although BMI 
classifications are arbitrary and their reliability is often disputed, they are commonly used 
clinically and do provide a rough indication of the level of an individual’s general adiposity 
(body fat)(Rothman, 2008; Sharma & Kushner, 2009). Adipose tissue (fat tissue) in the body, 
functions not only as an energy store, but also as a vital component of complex endocrine and 
metabolic signalling, and as such, adipose tissue has been previously considered one of the 
largest endocrine organs (Unamuno et al., 2018). Consequently, excessive adipose tissue 
deposition can alter its homeostatic function, and subsequently lead to the development of 
numerous obesity-related chronic diseases, for example cardiovascular disease (Wormser et 
al., 2011; Tandon et al., 2018). This link between adipose tissue and cardiovascular disease is 
at the core of the following research, investigating morphological changes to the adipose tissue 
surrounding the heart during obesity.  
 
While discussing the physiological effects of obesity, it is important to remember that the 
underlying processes that lead to obesity and obesity-related disease, are not inherently 
pathological. Instead (as is the case for any normal physiological process), it is the chronic 
persistence of obesity and subsequent over-activity of specific physiological processes, that is 
responsible for causing disease (Tandon et al., 2018). Obesity is a manifestation of the body’s 
physiological adaptation to store energy in times of excess, to be later utilised when energy is 
sparse. Unfortunately, as western society has evolved, this adaptation has become harmful in 
many individuals, due to the constant availability of energy rich foods, and lack of sufficient 
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daily exercise. This means the body is in a chronic state of energy surplus, energy which is 
subsequently stored in adipose tissue deposits throughout the body.  
 
1.1.1 Pathophysiology of obesity  
Surplus energy is converted to lipids and stored in fat cells called adipocytes (Sun et al., 2011). 
A chronic excess energy supply causes adipocytes to undergo remodelling whereby they 
enlarge (hypertrophy) as the amount of lipids created and stored in them increases 
(lipogenesis)(Sun et al., 2011). Additionally, this type of obesity-induced adipocyte 
remodelling is often accompanied by other pathological remodelling processes, such as 
inflammation and fibrosis triggered by hypoxia within the adipose tissue (Sun et al., 2011). 
Newly enlarged adipocytes can aggregate and form excess adipose tissue deposits, either 
subcutaneously (under the skin) or viscerally (surrounding organs), driving the overall 
expansion of fat tissue observed in obesity. This informs the known relationship between 
obesity measures (such as BMI) and adipocyte size (Muir et al., 2016; Aitken-Buck et al., 
2019a). Like all cells within the body, adipocytes contribute to a variety of homeostatic 
physiological processes, such as endocrine and metabolic signalling, inflammation and tissue 
remodelling (Zwick et al., 2018). Therefore, prolonged changes to adipocyte morphology (seen 
in obesity) can significantly alter the body’s normal physiological processes and produce 
pathophysiological outcomes (Tandon et al., 2018). 
 
1.1.2 Obesity and cardiovascular disease 
Recent studies have uncovered various links between obesity, cardiac remodelling, and a 
myriad of chronic diseases such as coronary artery disease, congestive heart failure and cardiac 
arrhythmias (Bhupathiraju & Hu, 2016). Observational studies of the general population have 
shown obesity to increase the risk of developing left ventricular hypertension, and be an 
independent predictor of left ventricular diastolic dysfunction (Bombelli et al., 2011; Kloch-
Badelek et al., 2012). A 1990 prospective study of 5000 men and women between the ages of 
28-62, showed obesity as an independent predictor of coronary artery disease (Hubert et al., 
1983). This study was backed up by a secondary post mortem study of over 3000 men aged 
15-34, which demonstrated that obesity in early adulthood, advances the progression of 
atherosclerosis years before the emergence of clinical indicators (McGill Jr et al., 2002). 
Additionally the 2005 INTERHEART study across 52 countries, showed a highly significant 
correlation between obesity and myocardial infarction incidence in the general population 
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(Yusuf et al., 2005). Mahajan et al., demonstrated that chronic obesity in sheep caused 
structural and hemodynamic, as well as electrophysiological remodelling, indicative of dilated 
cardiomyopathy, which consequently predisposed to these hearts to atrial fibrillation (a form 
of cardiac arrhythmia)(Mahajan et al., 2015). Alongside these cardiac effects, it is known that 
obesity increases one’s risk of dyslipidaemia, endothelial dysfunction and inflammation 
(Greulich et al., 2012). In a cohort study involving 1.2 million men and women of all ages, it 
was seen that each unit increment increase in BMI, was associated with a higher risk of 
coronary artery disease (Mongraw-Chaffin et al., 2015). 
 
Obesity studies like these consistently illustrate the pathological implication of obesity on the 
cardiovascular system long term, and substantial research has been done to uncover the 
possible mechanisms by which excess adipose tissue throughout the body, creates cardiac 
dysfunction (Romero-Corral et al., 2010). Despite meaningful advancements in knowledge, 
the complex nature of cardiovascular disease and obesity, has meant the exact role of the fat 
surrounding the heart in obesity related cardiomyopathies, has not been well characterised to 
date.  
 
1.2 Epicardial adipose tissue (EAT) 
Epicardial adipose tissue (hereafter referred 
to as EAT) is a component of the adipose 
tissue surrounding the heart. However 
unlike other adipose tissue here, such as 
pericardial adipose tissue (PAT), EAT is 
located within the visceral pericardium 
(Iacobellis, 2015)(figure 1.1). This unique 
anatomical location and lack of a fascial 
boundary between EAT and the 
myocardium (Iacobellis & Bianco, 2011), 
means EAT and the adjacent cardiac tissue 
(myocardium) share a coronary circulation, 
thus an intimate paracrine and vasocrine 
signalling relationship (Iacobellis et al., 
2005). This intimate relationship, suggests Figure 1.1 Anatomical location of epicardial adipose tissue 
(EAT) in relation to other cardiac structures.(Iacobellis, 2015) 
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that any changes in epicardial adipocyte morphology or localisation, could directly affect the 
structure and function of the adjacent myocardium.  
 
A novel finding by Mahajan et al. shows that PAT and EAT in obese hearts display dissimilar 
expansion characteristics (Mahajan et al., 2015). They noted hyperplasia of EAT adipocytes in 
obese individuals resulting in significant fatty infiltration into the atrial myocardium, while 
areas of PAT expansion did not show significant adipocyte infiltration into the adjacent 
myocardium. This discrepancy in remodelling characteristics, highlights a gap in knowledge 
which my study aims to fill. Particularly by addressing the possible effect of obesity on the 
morphology and localisation of EAT adipocytes, and any consequential effects on cardiac 
function. Various large clinical studies have also shown significant associations between 
excess EAT, and an increased risk of insulin resistance (Iacobellis et al., 2003; Pierdomenico 
et al., 2013b; Rabkin, 2014), coronary artery disease (Jeong et al., 2007; Xu et al., 2012) and 
atrial fibrillation (Wong et al., 2016). Furthermore, the associations observed between changes 
to EAT morphology and incidence of cardiovascular diseases, showed greater specificity in 
their diagnoses, than many of the diagnostic cardio-metabolic markers currently used in clinic 
(Wong et al., 2016). The above studies have contributed to the growing interest from many 
researchers, to investigate the role of EAT and changes to EAT morphology, in possible 
obesity-induced cardiac diseases. While advancements in knowledge have been made, as of 
yet, there have been few studies addressing the microscopic morphology of EAT (adipocyte 
size) in relation to the risk and prevalence of cardiovascular disease.  This is a gap in knowledge 
that my research aims to fill. 
 
Early in foetal development, EAT cell precursors diverge from other visceral adipose cell 
precursors, consequently EAT adipocytes are of mesodermal origin and undergo maturation 
directly adjacent to primordial cardiomyocytes (Nagy et al., 2017). This is dissimilar to PAT 
and subcutaneous (SAT) adipocytes which are of ectodermal origin, and consequently do not 
experience the same intimate relationship with cardiac tissue during their maturation (Sacks & 
Fain, 2007). This strengthens various propositions by earlier researchers (in response to 
observed inconsistencies between the morphology of EAT and other adipose tissues), 
suggesting that EAT physiology is inherently different to that of other adipose tissues under 
similar conditions. It is important to note that inherent differences in EAT morphology in 
relation to non-modifiable variables, such as an individual’s age and sex, also exist (Abbara et 
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al., 2006). A 2006 study showed that regardless of external variables, individuals aged 65+ had 
22% thicker EAT than those under the age of 65, additionally females had 17% more EAT than 
males (Abbara et al., 2006). Overall many dissimilarities between EAT and other adipose 
tissues throughout the body, in relation to anatomical location, expansion characteristics and 
embryonic origin can be observed. These dissimilarities highlight the unique nature of EAT, 
and present EAT as a tissue of interest in obesity-related research, to progress the current 
understanding of the complex pathophysiology of obesity and cardiovascular disease.  
 
1.2.1 Normal physiological role of EAT 
While investigating the pathophysiological role of EAT in obesity, it is important to understand 
the normal physiological role of EAT. Under normal physiological conditions, EAT (similarly 
to all adipose tissue) acts as an insulator, energy store, and is involved in numerous endocrine 
and metabolic signalling pathways, producing anti-inflammatory effects (Packer, 2018). EAT 
can also be cardio-protective against oxidative stress, and high levels of free fatty acids (FFAs), 
due to it’s unique ability of rapid FFA utilisation. However, like other adipose depots, under 
pathological conditions, EAT can also produce both pro-atherogenic and pro-inflammatory 
adipokines (Iacobellis et al., 2005; Iacobellis, 2014). The role of EAT as an insulator and 
metabolically active tissue, illustrates how it can affect in the electrophysiology, conduction, 
and voltage potentials throughout the heart, as well as cause remodelling and changes to the 
heart’s structural characteristics. 
 
1.2.2 EAT in obesity 
Until recently it was thought that adipose tissue deposits throughout the body responded 
similarly to a given physiological condition (such as obesity). However, as research into 
obesity and adipocyte physiology has progressed, researchers have uncovered distinct 
differences in the way that EAT responds to an obese environment, compared to the response 
of other visceral or subcutaneous adipose deposits (Greulich et al., 2011). This finding has 
contributed to the more recent characterisation of EAT thickness as a potential diagnostic tool 
for cardiovascular disease (Mancio et al., 2018). Under normal physiological conditions, EAT 
covers around 20-25% of the epicardial surface of the heart, however in obesity this can 
increase to almost 80% in some cases (Sacks & Fain, 2011). As previously discussed, the main 
mechanism of increased adipose tissue in obesity is through adipocyte hypertrophy. However, 
recent studies have shown that adipose tissue expansion in obesity, through an increased 
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number of adipocytes (hyperplasia) can occur in visceral fat (such as EAT) (Tandon et al., 2018). 
A 2019 study in post mortem cases showed that in obese patients, while subcutaneous adipose 
tissue (SAT), appendicular adipose tissue (AAT), PAT, and EAT all underwent an increase in 
tissue thickness, only SAT, AAT and PAT adipocytes underwent hypertrophy, while EAT 
adipocytes did not (Aitken-Buck et al., 2019a). Additionally, further histological examination 
uncovered that the increase in EAT thickness could not be attributed to an increase in non-
adipocyte tissues, such as fibrosis or inflammatory cells (Aitken-Buck et al., 2019b). This 
suggests that unlike adipocytes in other anatomical regions, the observed linear increase in 
EAT thickness with increased obesity, could be due to adipocyte hyperplasia.  
 
This hyperplasia-induced increase in EAT thickness in obesity, might provide insight into the 
mechanism by which obesity-induced changes to EAT morphology, predispose an individual 
to developing cardiac complications, and increase their risk of sudden cardiac death (Goeller 
et al., 2018). It has previously been shown that significant differences exist in the physiological 
function of adipose tissues that have undergone hyperplasia, compared to those that have 
undergone hypertrophy (Tandon et al., 2018). Additionally, this previous study found that the 
functional changes caused by adipocyte hyperplasia or hypertrophy in adipose tissues, were 
dissimilar between subcutaneous and visceral adipose tissues. While they did not address 
functional changes in EAT specifically due to adipocyte hypertrophy or hyperplasia, simply 
identifying differences highlights a gap for future research to fill. Of particular interest to this 
study are the possible structural changes to the myocardium as a result of changes in EAT 
morphology. Ventecleft et al., explored changes to the structure of the myocardium resulting 
from excess epicardial adipocyte activity in 2015 (Venteclef et al., 2015). They hypothesised 
that excess EAT (and thus excess EAT signalling) would induce myocardial fibrosis, and 
consequently disrupt cardiac conduction and lead to atrial fibrillation. In their sample of 39 
men and women undergoing cardiac surgery, their hypothesis was supported as they found that 
excess EAT induced global atrial fibrosis through certain adipokines released from the tissue. 
Additional preliminary studies have demonstrated that significant cardiac remodelling occurs 
due to infiltration of adipocytes (suggested to be of epicardial origin) into the myocardium, and 
that this remodelling plays a critical role in disease progression (Mahajan et al., 2015). Along 
with adipocyte infiltration, increased EAT thickness has also been shown to increase the risk 
of heart failure and myocardial infarction (Mancio et al., 2018). Recently Nalliah et al., showed 
in cardiac surgery patients, that EAT thickness and myocardial adipocyte infiltration was 
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significantly associated with changes in electrical conduction throughout the heart, and 
subsequent atrial fibrillation (Nalliah et al., 2020). These findings highlight the connection 
between morphological changes to EAT, and physiological changes to cardiac tissue, 
predisposing to cardiac diseases such as atrial fibrillation. 
 
It is important to note that in all adipose tissues, a homeostatic balance between the levels of 
hyperplasia and hypertrophy is maintained under normal conditions (Tandon et al., 2018). 
Thus, any changes to the ratio of hypertrophy and hyperplasia within fat depots, may result in 
an increased risk of chronic disease progression (Tandon et al., 2018). This was evidenced in 
2011 by Gealekman et al., who demonstrated that a non-uniform increase in subcutaneous or 
visceral adipose tissue, increased the risk of developing insulin resistance, a defining 
characteristic of type 2 diabetes mellitus (T2DM), and significant contributor to diabetic heart 
disease (Gealekman et al., 2011; Marsico et al., 2019). Additionally, it has been observed that 
the ratio of adipocyte size and adipocyte number in subcutaneous and visceral adipose tissues, 
fluctuates following obesity interventions such as bariatric surgery, physical activity or caloric 
restriction (Kim et al., 2009; Snel et al., 2012; Khalaf & Taegtmeyer, 2013). As all these 
interventions have proven to significantly reduce obesity and obesity-related complications 
(Picot et al., 2009), their beneficial effects are perhaps as a result of a renewed homeostatic 
ratio of adipocyte hypertrophy and hyperplasia.  
 
As well as the morphological and structural changes in EAT due to obesity, it is important to 
indicate that functional pathophysiological changes can also occur. Under pathophysiological 
conditions, EAT can become pro-inflammatory, releasing a combination of FFAs, and pro-
inflammatory adipokines such as activin-A, interleukin, and tumour necrosis factor alpha 
(Packer, 2018). These changes in signalling substances can produce their own 
pathophysiological effects on the myocardium, such as decreased contractility and stretch, 
altered conduction throughout the heart, and increased myocardial fibrosis, which only 
exacerbates cardiac dysfunction (Greulich et al., 2011). Overall, these obesity-induced 
morphological and functional changes to EAT, highlight the damaging cardiac effects of 
obesity, and the need for increased research into obesity-induced changed to EAT.  
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1.3 Societal and economic impacts of obesity and associated 
chronic disease in NZ 
As previously mentioned, both global and national epidemiological data, demonstrates that 
obesity is an ever-growing health issue, with an ever-increasing incidence, and affecting a more 
diverse range of individuals every year (Chooi et al., 2019). Worryingly, New Zealand is 
among the fattest nations in the world, in 2013, 30% of New Zealanders were classified as 
obese (Sharpe & Bradbury, 2015). Unfortunately, the problem is only worsening, currently 
New Zealanders have an average BMI of 28.6km/m2 , however this is projected to rise to 
30kg/m2 by the early 2030s (Wilson & Abbott, 2018). Aside from the previously discussed 
health and cardiovascular complications, what the statistics don’t show is that obesity confers 
a myriad of often-unseen effects on New Zealand’s society and economy. As the prevalence of 
obesity and related conditions is increasing in New Zealand, it is no surprise that the economic 
burden of these conditions is increasing also. In a report on New Zealand cost of illness studies 
published in 2009 by the Ministry of health, it was estimated that in 2004, $830 million was 
spent on direct and indirect costs of obesity in New Zealand (Jaine, 2009). This was an increase 
from $270 million in 1997, and 16 years later in 2020, while considering New Zealand’s 
observed increase in obesity prevalence, we can assume that these costs have only increased 
further.  
 
Societal effects emerge as such a large proportion of the population begin to experience 
decreased mobility and quality of life, disability, and subsequent mental health issues as a result 
of obesity and related cardiac dysfunction. For example, In 2016 obesity accounted for 9% of 
disability adjusted life years (Metrics & Evaluation, 2016). The effects of obesity on mental 
health are also well established (McCrea et al., 2012). A 2016 meta-analysis of New Zealand 
data, showed a strong relationship where obese and/or diabetic individuals had an 18% greater 
risk of developing depression (Mannan et al., 2016). Additionally, this study observed an 
increasing linear relationship between BMI and rates of antidepressant prescriptions (Mannan 
et al., 2016). It is also known that obesity has a strong genetic association, and that maternal 
obesity during pregnancy, predisposes the foetus to obesity and obesity-induced heart disease 
later in life (Goodarzi, 2018; Puppala et al., 2018; Ahmed & Delgado-Olguin, 2020). A 2020 
study by Ahmed et.al, showed that maternal pregnancy programs the foetal heart to develop 
adult onset cardiovascular disease (Reynolds et al., 2013), obesity (Reynolds et al., 2010) and 
diabetes (Hussen et al., 2015). These studies demonstrate that the combination of genetic and 
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maternal associations, contribute to a generational cycle of obesity. Worryingly, this cycle is 
already presenting itself in New Zealand, and can be witnessed through the increase in 
childhood obesity seen in recent years (Chiavaroli et al., 2019). This increase in childhood 
obesity, exposes the body of those affected, to prolonged periods of time under 
pathophysiological conditions, thus allowing more time for pathological cardiac remodelling 
to manifest. Overall this presents a crisis for the health outcomes of future New Zealanders, 
and illustrates the devastating impact of obesity and associated conditions on future 
generations. 
 
1.4 Ethnic differences in obesity and chronic disease  
In recent years with the rise of the obesity epidemic there have been many discoveries of 
genetic variances which predispose certain populations to weight gain, and the development of 
obesity (Stryjecki et al., 2018). As of late, researchers have gained new insights into the 
relationship between BMI and adipocyte hypertrophy in anatomically distinct adipose tissues, 
as well as the ethnic universality of observed trends in adipose tissue morphology (Aitken-
Buck et al., 2019a; Moharram et al., 2020a). Of particular interest is the finding of a strong 
genetic dependence of EAT (Nagy et al., 2017). A recent study done by the University of 
Adelaide showed that indigenous Australians presented with significantly greater macroscopic 
EAT volumes compared to their age, BMI and gender matched non-indigenous Australians, 
with similar subcutaneous fat levels (Sun et al., 2020). Similar studies have also been done in 
the United States, where they showed significant differences in visceral and total body fat 
volumes between African American and Caucasian people, in age and sex adjusted analysis 
(Staiano et al., 2013; Bello et al., 2019).  
 
While these findings reveal that genetic differences do exist between ethnic groups, the aims 
of this study specifically, are concerned with Māori, Pacific and NZ/European New Zealanders. 
The health inequities between these ethnic groups within New Zealand, and the disparities in 
obesity and associated chronic disease prevalence are well established (Reid & Robson, 2000). 
From the most recent Ministry of Health annual health survey, it was found that Māori adults 
are 1.8 times more likely, and Pacific adults are 2.5 times more likely to be obese than 
NZ/European adults. Additionally, Māori are 3.85 times more likely to suffer from heart 
failure, and 7.3 times more likely to have type 2 diabetes. Shockingly, Pacific adults are 8.25 
times more likely to suffer from heart failure, and 25.8 times more likely to have type 2 diabetes 
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(Health, 2019). With regards to ethnic differences in BMI and EAT thickness, a 2020 study 
found a linear relationship between increasing BMI and EAT thickness in NZ/European, but 
not in Māori or Pacific people (Moharram et al., 2020b). This suggests possible ethnic 
differences in the morphology and physiology of EAT, and consequential differences in how 
EAT responds to the obese physiological environment in the body. While currently this is a 
gap in the literature, it suggests a potential factor influencing the health outcomes of Māori and 
Pacific peoples, and highlights the need for further obesity related research in these 
populations. While the focus of this research is obesity and cardiovascular disease, let it be 
known that ethnic disparities in health outcomes span a multitude of diseases, including but 
not limited to, cancer, kidney disease, mental health, dental health and preventable diseases 
such as measles (Jamieson et al., 2016; Lawrenson et al., 2016; Huria et al., 2018). Of 
particular relevance in 2020 is the disparities in infection fatality rates of COVID-19, whereby 
Māori and Pacific New Zealanders are disproportionally effected (Steyn et al., 2020). It is also 
important to note that there are significant modifiable factors that influence health outcomes 
for Māori and Pacific populations in New Zealand. Low socio-economic status, racial bias and 
inaccessibility to healthcare and health education are among these (Reid & Robson, 2000). 
While these factors will not be addressed in my thesis, they are of critical importance when it 
comes to providing equitable healthcare in New Zealand. 
 
1.5 Importance of this research 
Developing a greater understanding of the relationship between EAT morphology and 
cardiovascular disease in obesity, is of critical importance when addressing the prevalence of 
these chronic conditions in New Zealand society. Additionally, further research will possibly 
illuminate the mechanisms behind why EAT so strongly indicates cardiac morbidity, which 
subsequently may improve diagnostic outcomes for patients. As a multicultural nation, striving 
to create a society with the greatest universal health outcomes possible, should be of vital 
importance. While New Zealand’s current health system is predominantly catered to the 
NZ/European majority of patients, the health disparities between majority and minority groups 
are blindingly clear (Huria et al., 2018). By increasing our understanding of how at risk, 
minority groups are predisposed to chronic obesity and cardiac disease, we can inform 
appropriate diagnosis and treatment options. We must do better to address areas of ethnic 
inequality in healthcare in New Zealand, both for the health of New Zealanders, and for the 
economic burden currently imposed by treating preventable diseases. Lastly, an improved 
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understanding of the diverse physiology of our assorted New Zealand population, will facilitate 
the implementation of appropriately targeted therapeutics, and early interventions, overall 
working to equalise health outcomes over all demographics. 
 
As discussed above, previous research has focused on EAT thickness (macroscopic 
morphology) as a novel diagnostic tool for cardiovascular disease. My research however, 
focuses predominantly on the microscopic (rather than macroscopic) morphological changes 
to EAT in obesity, and how these changes impact cardiac morphology. Additionally, my 
research will have a large focus on identifying differences between New Zealand’s indigenous 
(Māori) and NZ/European populations, something which previously has not been a focus of 
EAT research. Research regarding EAT morphology and its possible ethnic associations, 
addresses the possibility of using EAT as a novel and more accurate marker for heart disease 
risk, than the currently used, inadequate clinical indicators such as BMI. Developing more 
effective clinical diagnostic tools, improves early intervention and subsequent long term health 
outcomes for at risk individuals. 
 
1.6 Aims and hypothesis 
1.6.1 Aim one  
My first aim was to characterise the microscopic morphology of EAT in obesity, and 
substantiate previous research by determining how an increase in BMI correlates with 
adipocyte size in subcutaneous, appendicular, pericardial and epicardial adipose tissues. With 
this, my novel aim was to identify if adipocyte size/BMI relationships held true in New Zealand 
minority populations such as Māori and Pacific. In addition, I aimed to relate any microscopic 
adipocyte changes to the anthropomorphic and demographic parameters: age, sex, ethnicity, 
BMI, and cardiovascular disease presence. 
 
1.6.2 Hypothesis one 
I hypothesise that, as previously reported, BMI will demonstrate a positive linear relationship 
with adipocyte size in all fat depots except EAT, in post mortem cases. In addition, I 
hypothesise that this relationship between BMI and adipocyte size will not be conserved in the 
Māori or Pacific cases due to possible underlying genetic and/or physiological differences. 
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1.6.3 Aim two 
My second aim was to determine the localisation of adipocytes and fibrosis within the 
myocardium of post mortem cases, as well as to quantify the degree of myocardium-adipocyte 
contact area in the left ventricle. Lastly, I aimed to relate my findings to the aforementioned 
anthropomorphic and demographic parameters, and cardiovascular disease presence. 
 
1.6.4 Hypothesis two 
I hypothesise that post mortem cases with increased BMI, of Māori or Pacific ethnicity, female, 
or 65+ years old, will have a greater degree of adipocyte infiltration into the myocardium, 
accompanied by increased levels of myocardial fibrosis. Additionally, I expect those with 
increased fibrosis and adipocyte infiltration to be more likely to have suffered from 
cardiovascular disease and/or died from a cardiac event. I hypothesise that those with the worst 
health outcomes (for example cardiac death and cardiovascular disease) will have a greater 
contact area between the myocardium and adipocytes, as well as a greater number of adipocyte 
clusters within the myocardium. Lastly, I hypothesise that Māori and Pacific ethnicity will be 
an independent risk factor for myocardial adipocyte infiltration and myocardial fibrosis. (For 
example, for two age, sex and BMI matched cases, the Māori or Pacific case would present 
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My study consisted of the analysis of adipocyte tissue images and heart images from human 
post mortem cases, and their association with anthropomorphic and demographic information. 
 
2.1 Post-mortem case information 
This study was a part of an 18-month prospective study at Auckland City Hospital, Auckland, 
New Zealand, led by forensic pathologist Dr Rexson Tse. During this period, all cases that 
presented for post mortem examination underwent post mortem computed tomography 
(PMCT), and heart and adipose tissue examination and processing for histological analysis. 
This was as part of routine post mortem examination protocol and was authorised by the chief 
coroner. No tissue was retained following processing. In total for my research, a sample size 
of 50 cases was collected over 9 months, consisting of 37 males and 12 females. 
Anthropomorphic and demographic information for each case, such as bodyweight (kg), height 
(cm), heart weight (grams), cause of death, age, sex and ethnicity were available (for full details 
see appendix 1.1), while any potentially identifying information such as names or NHI numbers 
were blinded. The cases ranged from 18 to 82 years of age, with BMI ranging from 16.36 kg/m2 
to 40.26 kg/m2, and identified as either, NZ/European, Māori, Pacific, Asian or Indian ethnicity. 
Additional information regarding previous cardiovascular events as well as any underlying 
chronic health conditions such as type 2 diabetes mellitus, or hypertension was made available, 
along with any medications the individual was taking at time of death. Cases were excluded 
from the study if they were children (below 18 years of age), those with suspicious or homicidal 
cause of death, or those with potential medico-legal implications. Additionally, cases with 
advanced decomposition or trauma that resulted in loss of suitable tissue were excluded, and 
there were no malnourished and/or cachectic individuals included in the study. Two of the 50 
cases were excluded from analysis as one was a 13 year old paediatric patient, and one had no 
case information available, overall for my study 48 cases were used for analysis (case numbers 
45-101) .  
 
2.1.1 Combined case information 
For statistical analysis regarding adipose tissue data, 42 additional cases previously analysed 
by a different researcher in the Lamberts lab were added to my cohort of 48 to increase the 
statistical power. This additional data consisted of 43 cases, 16 females and 27 males ranging 
from 22 to 77 years of age with BMI ranging from 18.98 kg/m2 to 35.5 kg/m2. Again, these 
cases identified as either NZ/European, Māori, Pacific, Asian or Indian. The process of tissue 
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collection, processing and imaging (outlined below) for these cases was identical to my own, 
and was undertaken by the same forensic pathologist Dr Rexson Tse at Auckland Hospital. 
Consistency in image analysis between researchers was ensured by the use of identical methods 
(Aitken-Buck et al., 2019a), and was confirmed as both sets of data values were consistent with 
each other, and current literature. In total this meant that the cohort for analysis of mean 
adipocyte size compared to other variables was n=91, age ranging from 18 to 82 years and BMI 
ranging from 16.36 to 40.26 kg/m2. For full case details refer to appendix 1.1. 
 
2.2 Adipose tissue procurement 
All histological slices of adipose tissue were processed by Dr Rexson Tse. Adipose tissue 
biopsies were collected from four anatomically distinct sites (subcutaneous, appendicular, 
pericardial, and epicardial adipose tissues). Epicardial adipose tissue (EAT) biopsies were 
taken from the atrioventricular groove, between the right coronary artery orifice and the right 
lateral ventricular wall. Subcutaneous adipose tissue (SAT) was biopsied from the clavicle, 
appendicular adipose tissue (AAT) from adjacent to the appendix, and pericardial adipose 
tissue (PAT) from the external parietal pericardium. Of these samples the AAT and PAT were 
used as visceral adipose controls. 
 
2.3 Adipose tissue processing 
After procurement, the adipose tissue biopsy samples were immediately transferred to a 
histology cassette and immersed in 10% formalin for fixation. Samples were fixed for 24 to 48 
hours and transferred to an accredited histology processing laboratory (Department of 
Anatomical Pathology, Lab- PLUS, Auckland City Hospital). The biopsies were processed 
using the Leica Peloris Tissue Processor (Leica, Germany). This involved dehydration and a 
stepwise infusion of formalin, alcohol, xylene and finally paraffin wax. After tissue processing, 
the biopsies were embedded into paraffin wax and sectioned at 4µm using a Thermo scientific 
HM325 microtome (ThermoFisher Scientific, USA). Sectioned tissues were then stained using 
Haematoxylin and Eosin using an automated Leica Multistainer model ST5020 (Leica 
Biosystems, Germany) (full staining protocol see appendix 1.2). The histological slides were 
viewed on an Olympus BX53 microscope (Olympus, Japan) using an UPlanFL N 20x objective 
lens. One digital image was taken of each biopsy using an Olympus UC50 (Olympus, Japan) 
or an AmScope HD1080A (AmScope, United States) digital camera. Images were then 
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transferred to the Lamberts Lab for digital analysis of adipocyte size and non-adipocyte area. 
(Aitken-Buck et al., 2019a) 
 
2.4 Adipose tissue image analysis 
Digital analysis of adipose tissue images was conducted using Aperio Imagescope software 
(Leica Biosystems pathology imaging, Germany). The researcher was blinded to all case 
information while conducting image analysis so as to eliminate bias from the data collection 
process. Images of adipocyte histology were provided from each of the 4 aforementioned 
anatomically distinct adipose depots (subcutaneous, appendicular, pericardial and epicardial) 
for a total of 48 cases.  
 
2.4.1 Analysis of microscopic adipocyte morphology 
Aperio Imagescope software (Leica Biosystems pathology imaging, Germany) was used to 
measure the microscopic morphology of adipocytes in each case. Using the histological images 
from the adipose tissue biopsies, individual adipocytes in each image were identified and 
circled by hand using the positive pen tool. Any adipocytes with disrupted or indistinguishable 
cell membranes were excluded from the selection process. Additionally, cells that were 
partially out of frame were not measured nor analysed. The circumference and area of each 
adipocyte was measured based on pixel size per μm2, which at the 20x objective lens used for 
imaging equated to 0.28899 microns per pixel. This data along with the number of cells per 
image was exported to Microsoft Excel (ExcelTM 2013, Microsoft Corp., WA, USA) where 
the mean adipocyte area and the number of adipocytes in each image was calculated. This 
process was repeated for analysis of the images of EAT, AAT, SAT and PAT for all 48 cases. 
The accuracy of this measurement by hand was ensured by comparison of data collected by the 
researcher from 5 randomly selected images, to data collected from the same 5 images by an 
independent researcher with experience using this technique. The data collected by both parties 
exhibited a variation of under 1% between each sample which validates the accuracy of data 
collection. Additionally, the collected adipocyte size averages, were compared to current 
literature and demonstrated consistency with known information regarding adipocyte size. 
2.4.2 Analysis of non-adipocyte area 
Aperio Imagescope software (Leica Biosystems pathology imaging, Germany) was used to 
measure the total non-adipocyte area in each of the 48 histological images of EAT adipocyte 
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depots. This variable was measured to demonstrate that any changes observed in the 
morphology of EAT in each case was attributed to changes in the adipocytes rather than to 
changes in fibrosis, vascularisation or inflammatory cells. Non-adipocyte area was classified 
as areas of the image that showed fibrosis, extra cellular matrix, blood vessels or other non-
adipocyte cells such as inflammatory or immune cells for example mast cells. This was 
identified by hand and calculated as a percentage of the total image area. 
 
2.4.3 Unit conversion 
Unit conversions had to be performed before analysis could take place to ensure that all 
measurements were to scale and areas were in µm2. For mean adipocyte size data from 
subcutaneous, appendicular, pericardial and epicardial adipose depots, a magnification of 20x 
was used for imaging, this combined with the specifications of the microscope and digital 
camera used meant that a magnification of 0.28899 microns per pixel was used to convert the 
mean adipocyte areas to µm2.  
 
2.5 Heart tissue procurement 
All histological slices of heart tissue (myocardium) were processed by Dr Rexson Tse. Hearts 
were removed and weighed before being fixed in 10% formaldehyde. Standardised transverse 
myocardial slices were obtained from each chamber of the heart (left atrium, right atrium, left 
ventricle, right ventricle) as part of routine post-mortem cardiac examination.  
 
2.6 Heart tissue processing 
After procurement, the heart tissue (myocardial) biopsies were processed, embedded and 
sectioned (4µm) similarly to the adipose tissue. Each section was stained for Masson Trichrome 
using the Ventana Stainer automatic procedure (appendix 1.3). Masson Trichrome stained the 
cardiomyocytes red, fibrosis blue and adipocytes and background area white. The tissue on the 
slides were dewaxed, hydrated and treated with Bouin’s fixative for 1 hour at 60°C in an oven 
and cooled for 10 minutes. The slides were then washed and put into the automatic multistainer 
and stained sequentially with Weigert’s Haematoxylin and Biebrich Scarlet-Acid Fuschsin for 
10 minutes. Samples were then differentiated in Phosphomolybidic/Phosphotungstic acid for 
15 minutes, counter stained in Aniline blue for 6 minutes, and differentiated in 1% acetic acid 
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for three minutes. In each step of staining, differentiating, and counterstaining, the slides are 
washed in water. Finally, the slides were dehydrated, cleared and mounted.  
 
Following staining, the slides were viewed on an Olympus BX53 microscope (Olympus, Japan) 
using a UPlanFL N 4x objective lens. One digital image was taken of each sample using either 
an Olympus UC50 digital camera (Olympus, Japan) or an AmScope HD1080A digital camera 
(AmScope, United States). Images were then transferred to the Lamberts Lab at the Department 
of Physiology, University of Otago, Dunedin for digital analysis. These images were used to 
identify the fibrotic, cardiomyocyte, adipocyte and myocardium-adipocyte contact area in each 
left ventricle section. This enabled evaluation of the degree of fatty infiltration into distinct 
anatomical locations within the heart muscle, and allowed analysis of how this associates with 
fibrosis and overall heart function.  
 
2.7 Heart tissue image analysis 
Adobe Photoshop software (Adobe, United States) was used to analyse the fibrotic and 
cardiomyocyte areas within the histological image of the left ventricle from each case. 
Unfortunately, images of the left ventricle were only available for 27 out of the total 101 cases, 
therefore for left ventricular analysis n=27 (23 male, 4 female). Firstly, individual clusters of 
adipocytes in each image were identified and circled by hand using the lasso tool, the number 
of adipose pixels was recorded as well as the total number of pixels in the image (figure 2.1). 
Next the white background space within the tissue (created during tissue processing due to 
separation of myocyte striations) was selected and removed from the image to find the total 
number of pixels of cardiac tissue within the image. This meant that fibrosis and adipocyte 
infiltration could be calculated as a percentage of total tissue area excluding the background 
space. Analysis of heart tissue biopsies was conducted only for samples from the left ventricle 
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2.7.1 Creating a mask for heart tissue image analysis 
Two Photoshop masks were created, one to identify fibrosis and the other to identify 
cardiomyocytes. As the heart tissue was stained with Mason trichrome stain, the differences in 
colour between fibrosis (blue) and cardiomyocytes (red) meant the mask could work by 
identifying all the pixels of the same colour in a given image. A mask for red pixels (for 
identification of myocytes) and a mask for blue pixels (for identification of fibrosis) were 
created using the average red and blue shades of myocytes and fibrosis respectively in a sample 
of five randomly selected images. This was necessary to create a mask that accurately identified 
each feature for the majority of the images, as each image presented with varying degrees of 
intensity, saturation, and shade of staining. To create the fibrosis mask starting with the first 
image the ink dropper tool was used to select areas of blue fibrosis across the entirety of the 
image, in order to pickup various shades of blue representing fibrosis. This was then saved and 
applied to the next image before selecting additional shades of blue from the second image and 
so on. This was repeated on all of the five randomly selected images and by the last image the 
Figure 2.1 Photoshop image of left ventricle histology from case 76 showing selected adipocyte 
area. 
Masson Trichrome staining, red: cardiomyocytes, blue: fibrosis, white: adipocytes. Black and white line: 
outline of adipocyte area. 
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mask was able to identify a variety of shades of blue present across images with various 
staining characteristics, providing a reliable mask to use for identification of fibrosis on all 
images. This process was repeated for the creation of the cardiomyocyte mask but with 
identification of shades of red coloured pixels rather than blue. Both masks were checked for 
accuracy by an independent researcher with experience using this technique. Both masks were 
applied to every left ventricle image to identify the number of myocyte and fibrosis pixels in 
each image (figure 2.2) which was later converted to an area in µm2 and eventually a percentage 
of total left ventricular cardiac tissue. There were two images in which the mask did not 
accurately select the areas of fibrosis and cardiomyocytes therefore they were excluded from 
analysis creating a total n=25. 
 
 
This technique was favoured over the technique of identifying fibrosis and myocyte area by 
hand (as was used to identify adipocyte area) for a number of reasons. Firstly, as the heart tissue 
images were taken at a lower magnification (4x objective) compared to the adipose tissue 
images, it was more difficult to accurately distinguish the boundaries between areas of fibrosis, 
cardiomyocytes, adipocytes and background space by hand. Secondly, due to the nature of the 
tissue, and general difference in cell morphology of fibrotic and cardiomyocyte areas, it meant 
their cellular boundaries were less defined compared to the adipocyte boundaries, again making 
them harder to accurately identify by hand. Lastly the histological samples for analysis of 
cardiac tissue presented with a significant amount of spacing (white) between striations of 
cardiomyocytes, which is a known histological processing artefact that would not be present in 
A: B: 
Figure 2.2 Photoshop images from case 76 showing areas selected using the myocyte and fibrosis masks in Photoshop.  
 
A: red pixels identified with myocyte mask in Photoshop B: blue pixels identified with fibrosis mask in Photoshop 
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vivo. Due to the size of these intermittent areas of white background space, it was not possible 
to accurately remove them by hand. Taking all of this into account, it was obvious that the 
method of using a mask enabled the most accurate measurement of total fibrotic or 
cardiomyocyte area per image.  
 
2.7.2 Analysis of fibrotic area 
To identify the fibrotic area in the images of heart tissue biopsies from the left ventricle of each 
case, the fibrosis mask created in Photoshop as outlined above was applied. The fibrotic area 
was recorded as number of pixels, and was subsequently converted to an area (µm2) and 
percentage of total tissue area (as outlined in 1.10.1). This measurement was used to quantify 
the relative fibrotic area in relation to relative cardiac area in the left ventricle, which gives an 
indication of cardiac contractility and overall function. 
 
2.7.3 Analysis of cardiomyocyte area 
To Identify the total cardiomyocyte area in the images of heart tissue biopsies from the left 
ventricle of each case, the cardiomyocyte mask created in Photoshop as outlined above was 
applied. Again, as outlined above the area was recorded as the number of pixels, and was 
subsequently converted to an area (µm2) and percentage of cardiomyocytes in the total tissue 
area. This measurement was used to quantify the relative cardiomyocyte area within each 
sample from the left ventricle. 
 
2.7.4 Unit conversion in Photoshop 
Unit conversions had to be performed before analysis could take place to ensure that all 
measurements were to scale and areas were in µm2. The data gathered in Photoshop was 
recorded as number of pixels and was subsequently converted to area in µm2. These images 
were either 5072480 Or 5007744 pixels per image depending on whether they were a tif or jpg 
file respectively. This total pixel number represents an area of 10.5mm2 which is the area within 
each left ventricular image. The conversion from pixels per image to area in µm2 were therefore 
x2.06999 and x2.09675 respectively. This same conversion was then used to convert the 
adipocyte, fibrosis and myocyte areas from pixels to µm2. 
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2.7.5 Analysis of adipocyte localisation  
Using the histological images from myocardial biopsies of the left ventricle of each case, 
Aperio Imagescope software was used to individually identify and circle adipocyte clusters by 
hand using the positive pen tool. The identification of adipocytes in Imagescope was consistent 
with the adipocytes identified in Photoshop as a screenshot of each image after adipocyte 
identification in Photoshop, was taken and used as a reference for identification in Imagescope. 
A cluster was defined as one or more adipocytes aggregated together within the boundaries of 
the image. Unlike the measurements taken for microscopic adipocyte morphology analysis, 
clusters that were partially out of frame were still included in the analysis of adipocyte 
localisation. This was because the analysis of adipocyte localisation was not measuring 
individual cell size and instead focused on total adipocyte area within a given area of 
myocardium. Additionally, a significant number of clusters were too large to fit completely 
within the boundaries of the image, but to exclude these would yearn a false representation of 
total adipocyte area. Again the area of each adipocyte cluster was measured based on microns 
per pixel, which at the 4x objective lens used for imaging equated to 0.41758 microns per pixel. 
This data was then exported to Microsoft Excel (ExcelTM 2013, Microsoft Corp., WA, USA) 
for statistical analysis. Total adipocyte area was used to quantify the degree of adipocyte 
infiltration and localisation within the myocardium, and the relative adipocyte area in relation 
to fibrotic and myocardial areas.  
 
2.7.6 Analysis of myocardium-adipocyte contact area 
Lastly the myocardium-adipocyte contact area was measured again using Aperio imagscope. 
The positive pen tool was used to individually draw a line along the circumference of any 
adipocyte where it came in direct contact with myocardium (appendix 1.6). The length along 
any side of an adipocyte cluster that was on the boarder of the image and any contact area with 
fibrosis was not included in the total myocardium-adipocyte contact area. This contact area 
was given in microns per pixel which at the 4x objective lens used for imaging equated to 
0.41758 microns per pixel. This data was then exported to Microsoft Excel (ExcelTM 2013, 
Microsoft Corp., WA, USA) for statistical analysis. Analysing the myocardium-adipocyte 
contact area gives an indication of the intensity of adipocyte infiltration into the myocardium. 
This is important because adipocytes can release various factors that can act on the myocardium 
effecting contractility. Thereby it is inferred that a greater contact area between adipocytes and 
adjacent cardiomyocytes, might result in a larger paracrine adipose capacity.  
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2.7.7 Unit conversion 
Unit conversions had to be performed before analysis could take place to ensure that all 
measurements were to scale and areas were in µm2. To convert the data from the left ventricular 
images to areas in µm2 and lengths in µm, a magnification of 0.41758 microns per pixel was 
used as these images were taken using the same microscope and digital camera using a 4x 
objective lens.  
 
2.8 Secondary data analysis 
Importantly, all case information was provided separately to the images, and the researcher 
was blinded to this information for the duration of image analysis. All statistical analysis and 
graphing was performed in GraphPad PrismTM 8 file (GraphPad Software Inc., CA, USA). 
The first round of statistical analysis was undertaken to compare the variables: mean adipocyte 
size in each of the 4 adipose tissue depots (SAT, AAT, PAT, EAT), BMI, ethnicity, sex, and 
age. This was done using the combined cohort of 91 cases. The second round of statistical 
analysis was to compare data gathered from the analysis of left ventricular images. 
Comparisons were done using the variables: percentage fibrotic area, percentage adipocyte 
area, number of adipocyte clusters, myocardium-adipocyte contact area. These variables were 
compared to all of the aforementioned variables, as well as cardiovascular disease prevalence, 
heart weight and cause of death. 
2.9 Statistical analysis of mean adipocyte size and case details  
2.9.1 Mean adipocyte size in SAT, AAT, PAT and EAT depots 
The mean adipocyte size for each case in each adipose depot was calculated in Microsoft Excel 
(ExcelTM 2013, Microsoft Corp., WA, USA) and imported into GraphPad PrismTM 8 file 
(GraphPad Software Inc., CA, USA) for subsequent analysis. A one-way ANOVA was 
conducted comparing the mean adipocyte size of each depot as a group, as well as for individual 
cases. A subsequent one-way ANOVA was conducted to identify a linear trend in adipocyte 
size between depots. Additionally a multiple variable correlation matrix was conducted to rule 
out BMI, age and sex as confounders of the data before a multiple linear regression analysis 
was done to validate this. 
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2.9.2 NZ/European mean adipocyte size vs BMI in NZ/European, Māori 
and Pacific populations 
For each of the data sets of mean adipocyte size, a ROUT (Q=1%) outlier test was conducted 
to remove outliers. Next, a simple linear regression analysis was conducted to assess the 
relationship between BMI and mean adipocyte size in each of the adipose depots (SAT, AAT, 
PAT and EAT) individually.  
 
2.9.3 Mean adipocyte size vs anthropomorphic and demographic variables 
To identify any potential correlations between SAT, AAT, PAT and EAT adipocyte size, age, 
sex, BMI and ethnicity, a Pearson r correlation matrix was performed to give an indication of 
correlations between variables thus suggesting areas for further analysis.  
 
2.10 Statistical analysis of left ventricular data  
Firstly, the pixels of white background space in each image was subtracted from the total pixels 
in that image. The percentage of fibrosis, adipocytes and myocytes was then calculated by 
dividing the number of pixels for each of these areas by the number of pixels in the image (after 
background white was removed). Percentages were recorded to 2 decimal place and were 
calculated before unit conversion to µm2 to maintain the specificity of each percentage. The 
total adipocyte area in each left ventricular image along with the total myocardium-adipocyte 
contact area was calculated in Microsoft Excel (ExcelTM 2013, Microsoft Corp., WA, USA) 
and imported into GraphPad PrismTM 8 file (GraphPad Software Inc., CA, USA) for 
subsequent analysis. A dot plot graph and simple linear regression analysis were performed to 
characterise any relationship between BMI and adipocyte infiltration or myocardial fibrosis. 
Subsequently, ROUT (Q=1%) outlier tests were performed on the left ventricular data before 
Pearson r correlation matrixes were made for the total population, and individually for 
NZ/European and Māori/Pacific. These highlighted interesting correlations between variables 
for further investigation. A simple linear regression analysis was performed comparing 
adipocyte size and myocardial fibrosis, as well as for EAT adipocyte size compared to 
adipocyte infiltration, and heart weight compared to BMI. Lastly a two way ANOVA was 
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3.1 Adipocyte size analysis using combined data sets 
The data used for this analysis was the data collected by the researcher combined with data 
collected by a previous student in the Lamberts Lab in 2019 as a part of the same study. To 
ensure consistency was maintained between researchers, the same software, technique and 
image magnification was used for analysis, additionally the two researchers reported similar 
means in their data sets and the values were consistent with current literature. The two data sets 
were combined for analysis of mean adipocyte size and anthropomorphic and demographic 
variables to improve the statistical power of the data. The overall n value for patients in the 
study was n=48 (collected by the researcher) plus n=43 (collected by the previous student) to 
make an overall n=91. However, one case (case 38) did not have data for mean AAT adipocyte 
size therefore n=90 for AAT data. 
 
3.1.1 Differences between EAT, PAT, SAT and AAT adipocyte size 
In line with previous works (Aitken-Buck et al., 2019a) it was found that in the sample of the 
total study population, mean adipocyte size was significantly smaller in pericardial and 
epicardial depots compared to subcutaneous and appendicular depots (figure 3.1A). Adipocyte 
size was normalized to age, sex and BMI using multiple linear regression and mixed effects 
analysis. The mean SAT adipocyte size was 5120µm2, mean AAT adipocyte size was 5087µm2, 
mean PAT adipocyte size was 2960µm2, and the mean EAT adipocyte size was 2805µm2. A 
one-way ANOVA was performed and showed that PAT mean adipocyte size was significantly 
smaller than SAT mean adipocyte size (p<0.0001), and AAT mean adipocyte size (p<0.0001). 
EAT mean adipocyte size was also significantly smaller than SAT mean adipocyte size 
(p<0.0001) and AAT mean adipocyte size (p<0.0001). However, there was no significant 
difference between the mean adipocyte size of SAT and AAT groups, nor PAT and EAT groups 
(p=0.9997, p=0.9745 respectively).  
 
In the NZ/European population a similar relationship was observed, the mean SAT adipocyte 
size was 4648µm2, mean AAT adipocyte size was 5065µm2, mean PAT adipocyte size was 
3172µm2, and mean EAT adipocyte size was 2903µm2. Again, SAT mean adipocyte size was 
significantly larger than PAT or EAT mean adipocyte sizes (p=0.021, p=0.0002 respectively). 
AAT mean adipocyte size was also significantly larger than both PAT and EAT mean 
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adipocyte sizes (p<0.0001) (figure 3.1B). There was no significant difference between SAT 
and AAT mean adipocyte sizes (p=0.7385) nor PAT and EAT mean adipocyte sizes 
(p=0.9133). 
In the Māori population, the mean SAT adipocyte size was 6269µm2, mean AAT adipocyte 
size was 4584µm2, mean PAT adipocyte size was 2129µm2, mean EAT adipocyte size was 
Figure 3.1 Mean adipocyte size (µm2) in subcutaneous (SAT), appendicular (AAT), pericardial (PAT) and 
epicardial (EAT) adipose tissues in Total (n=91), NZ/European (n=57), Māori (n=16) and Pacific (n=6)  
populations 
A: The total population, SAT adipocyte size is significantly larger than PAT and EAT adipocyte size # = p<0.0001, 
AAT adipocyte size is significantly larger than PAT and EAT adipocyte size * = p<0.0001. SAT, PAT, EAT n=91, AAT 
n=90. B: NZ/European population, SAT adipocyte size is significantly larger than PAT adipocyte size # = p=0.021, and 
EAT adipocyte size # =p=0.0002. AAT adipocyte size is significantly larger than PAT and EAT adipocyte size * = 
p<0.0001. SAT, AAT, PAT, EAT n=57. C: Māori population, SAT adipocyte size is significantly larger than PAT 
adipocyte size # = p=0.0099, and EAT adipocyte size # = p=0.0165. SAT, PAT, EAT n=16, AAT n=15. And D: Pacific 
population, SAT, AAT, PAT, EAT n=6. Calculated using a one-way ANOVA and post hoc Tukey’s multiple 
comparison test. Results are normalized to BMI, sex and age using a multiple linear regression and mixed effect analysis 
and are presented as mean ± SEM.  
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2361µm2. Again, SAT mean adipocyte size was significantly larger than both PAT and EAT 
mean adipocyte sizes (p=0.0099, p=0.0165 respectively) (figure 3.1C). Interestingly, there was 
no significant difference between AAT mean adipocyte size and PAT nor EAT mean adipocyte 
sizes (p=0.24, p=0.3232 respectively). There was also no significant difference between SAT 
and AAT mean adipocyte sizes (p=0.5649) nor PAT and EAT mean adipocyte sizes 
(p=0.9978). However, there was a significant trend revealed through a one-way ANOVA 
mixed effects trend analysis, showing a linear decrease in adipocyte size moving from SAT, to 
AAT, PAT and EAT (p=0.0009).  
 
In the Pacific population, the mean SAT adipocyte size was 4754µm2, mean AAT adipocyte 
size was 5268µm2, mean PAT adipocyte size was 2496µm2, and mean EAT adipocyte size was 
2595µm2. However, no significant difference between the mean adipocyte in any of these areas 
existed (figure 3.1D).  
 
3.2 Relationship between BMI and adipocyte size in total 
population 
In the total cohort, BMI showed a significant linear relationship with subcutaneous (SAT) mean 
adipocyte size (P=0.0016, r2=0.11, figure 3.2A), appendicular (AAT) mean adipocyte size 
(P=<0.0001, r2=0.24, figure 3.2B), and pericardial (PAT) mean adipocyte size (P=0.0016, 
r2=0.1132, figure 3.2C). However, there was no significant relationship seen between BMI and 
epicardial (EAT) mean adipocyte size (P=0.7060, figure 3.2D).  
 
3.3 Relationship between BMI and adipocyte size in the New 
Zealand/European population 
In the NZ/European population, a ROUT Q=1% outlier test was done on the PAT adipocyte 
size data, and a subsequent univariate linear regression analysis was performed. As a result, 
the same linear relationship between BMI and mean adipocyte size in SAT (p=0.0128, 
r2=0.1075, figure 3.3A), AAT (p=0.0018, r2=0.1642, figure 3.3B) and PAT (p=0.0023, 
r2=0.165, figure 3.3C) depots was observed, as was seen in the total population. Additionally, 
as observed in the total population results, EAT mean adipocyte size did not show a linear 



















Figure 3.2 Univariate linear regression analysis of BMI and mean adipocyte size in subcutaneous (SAT), 
appendicular (AAT), pericardial (PAT), and epicardial (EAT) adipocyte size in the total population 
A:  subcutaneous (SAT) P=0.0016, r2=0.11, B: appendicular (AAT) P=<0.0001, r2=0.24, C: pericardial (PAT) 
P=0.0016, r2=0.1132, and D: epicardial (EAT) P=0.7060. SAT, PAT, EAT n=91, AAT n=90. All values 









Figure 3.3 Univariate linear regression analysis of BMI and mean adipocyte size in subcutaneous (SAT), 
appendicular (AAT), pericardial (PAT), and epicardial (EAT) adipocyte size in the New 
Zealand/European population 
A: subcutaneous (SAT) p=0.0128, r2=0.1075, B: appendicular (AAT) p= 0.0018, r2=0.1642, C: pericardial 
(PAT) p=0.0023, r2=0.165, and D: epicardial (EAT) p=0.4138 adipose tissues in NZ/European population. 
Calculated using a ROUT (Q=1%) outlier test and simple linear regression. SAT, AAT, EAT n=57, PAT n=54. 
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3.4 Relationship between BMI and adipocyte size in Māori and 
Pacific populations 
Analysis of data from Māori and Pacific populations was done separately, however due to the 
low sample numbers of Pacific patients (n=6), any findings must be taken only as an indication 
of what may present in the total Pacific population. Unlike what was seen in the total and 
NZ/European populations, in the Māori population there was no significant relationship 
between BMI and mean adipocyte size in SAT (p=0.6707), unless a ROUT (Q=1%) outlier test 
was done (p=0.0135, r2=0.3854, figure 3.4A). When this was done, the Māori population 
demonstrated the same relationships between mean adipocyte size and BMI as seen in the 
NZ/European population (figures 3.3-3.4). Interestingly, the Pacific population demonstrated 
Figure 3.4 Univariate linear regression analysis of BMI and mean adipocyte size in subcutaneous (SAT), 
appendicular (AAT), pericardial (PAT), and epicardial (EAT) adipocyte size in the Māori and Pacific populations 
A: subcutaneous (SAT), Māori (red line): p=0.0135, r2=0.3854, Pacific (brown line): p=0.0196, r2=0.7806, B: 
appendicular (AAT), Māori p=0.0017, r2=0.5442, Pacific p=0.0632 C: pericardial (PAT), Māori p=0.001, r2=0.5482, 
Pacific p=0.8079 and D: epicardial (EAT), Māori: p=0.3163, Pacific: p=0.2853 adipose tissues in Māori and Pacific 
populations. Calculated using a ROUT (Q=1%) outlier test and simple linear regression. Māori SAT, AAT n=15, PAT, 
EAT n=16. Pacific SAT, AAT, PAT, EAT n=6. 
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a very significant linear relationship with a high r2 value, between BMI and mean SAT 
adipocyte area (p=0.0196, r2=0.7806, figure 3.4A). In the AAT samples, the mean adipocyte 
sizes in Māori patients showed a significant linear relationship with BMI (p=0.0017, 
r2=0.5442), while even when outliers were removed, this was not the case for the Pacific cases 
(p=0.0632, figure 3.4B). This finding was replicated in the PAT samples where Māori cases 
demonstrated a significant linear relationship between BMI and PAT mean adipocyte size 
(p=0.001, r2=0.5482), while in Pacific cases there was no significant relationship (p=0.8079, 
figure 3.4C). Lastly in the EAT samples there was no linear relationship between BMI and 
mean adipocyte size in either the Māori or Pacific populations (Māori: p=0.3163, Pacific: 
p=0.2853, figure 3.4D). 
 
3.5 Correlation between adipocyte size and 
anthropomorphic/demographic variables 
A Pearson r correlation matrix was performed between mean adipocyte sizes in SAT, AAT, 
PAT and EAT, age, sex, BMI and ethnicity in the total sample population. This was done to 
find any significant correlations between these variables and provide an indication of focus 
points for further statistical analysis. Firstly, a significant positive correlation was identified 
between the mean adipocyte size in each of the adipose tissue depots SAT, AAT, PAT and 
EAT (SAT/AAT p<0.0001 r=0.42, SAT/PAT p=0.002 r=0.33, SAT/EAT p=0.003 r=0.31, 
AAT/PAT p<0.0001 r=0.58, AAT/EAT p<0.0001 r=0.58, PAT/EAT p<0.0001 r=0.81, figure 
3.5A). A negative correlation was also identified between AAT mean adipocyte size and sex 
(p=0.049, r=-0.21). This correlation indicates that on average, men have a larger mean AAT 
adipocyte size than women (as sex had to be entered as a binomial variable therefore male=1 
and female=2). However, it is important to note that this data was not normalised to body size 
(BMI, height or weight), and it can be assumed that these body size variables would have an 
impact in adipocyte morphology, therefore this relationship may not be reliable. Additionally, 
a significant positive correlation was also identified between both PAT and EAT mean 
adipocyte sizes and age (PAT: p=0.003 r=0.31, EAT: p=0.038 r=0.22). Lastly there was a 
positive correlation identified between BMI and mean SAT and AAT adipocyte size, consistent 
with previous findings (SAT: p=0.04 r=22, AAT: p<0.0001 r=0.40). 
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3.5.1 Correlation between adipocyte size and 
anthropomorphic/demographic variables in NZ/European 
population 
The significant positive correlation between mean adipocyte size in all of the adipose depots 
(SAT, AAT, PAT and EAT) was maintained in the NZ/European population (SAT/AAT 
p<0.0001 r=0.71, SAT/PAT p<0.0001 r=0.74, SAT/EAT p<0.0001 r=0.75, AAT/PAT 
p<0.0001 r=0.62, AAT/EAT p<0.0001 r=0.59, PAT/EAT p<0.0001 r=0.84, figure 3.5B). The 
relationship between age and mean PAT adipocyte size was also maintained (p=0.008 r=0.35) 
with the addition of a similar positive correlation between age and AAT mean adipocyte size 
(p=0.004 r=0.38), while the relationship between age and EAT mean adipocyte size was not 
evident (p=0.055). The previously observed relationship between sex and AAT mean adipocyte 
size, was also seen in the NZ/European population (p=0.048 r=-0.26), as was the BMI 
Figure 3.5. Pearson r correlation matrix heat map graph demonstrating correlations between various patient 
variables in total (A) and New Zealand/European (B) populations 
Values are r values demonstrating the degree of correlation between 2 variables. The closer to 1, the stronger the 
variable. Blue squares denote a positive correlation while red squares denote a negative correlation. # = p<0.05, * = 
p<0.005. A: Significant positive correlations identified between mean adipocyte size in all adipose depots (SAT/AAT 
p<0.0001, SAT/PAT p=0.002, SAT/EAT p=0.003, AAT/PAT p<0.0001, AAT/EAT p<0.0001, PAT/EAT p<0.0001). 
Significant negative correlation seen between AAT mean adipocyte size and sex (p=0.049 r=-0.21). Significant 
positive correlation found between age and PAT and EAT mean adipocyte size (PAT: p=0.003 r=0.31, EAT: p=0.038 
r=0.22). Significant positive correlation between BMI and SAT and AAT mean adipocyte sizes (SAT: p=0.04 r=22, 
AAT: p<0.0001 r=0.40) n=91 B: Significant positive correlation observed between mean adipocyte size in all adipose 
depots (SAT/AAT p<0.0001 r=0.71, SAT/PAT p<0.0001 r=0.74, SAT/EAT p<0.0001 r=0.75, AAT/PAT p<0.0001 
r=0.62, AAT/EAT p<0.0001 r=0.59, PAT/EAT p<0.0001 r=0.84). significant relationship observed between age and 
PAT and AAT mean adipocyte size (PAT: p=0.008 r=0.35, AAT: p=0.004 r=0.38). Significant correlation observed 
between sex and AAT mean adipocyte size (p=0.048 r=-0.26) Significant positive correlation also identified between 
BMI and age, and SAT and AAT mean adipocyte size (BMI/Age p=0.038 r=0.28, BMI/SAT p=0.013 r=0.33, 
BMI/AAT p=0.002 r=0.41) 
A: B: 
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compared to SAT and AAT mean adipocyte size relationship (SAT: p=0.013 r=0.33, AAT: 
p=0.002 r=0.41). Lastly, a significant positive correlation was observed between BMI and age 
(p=0.038 r=0.28) 
 
3.5.2 Correlation between adipocyte size and 
anthropomorphic/demographic variables in Māori population 
Interestingly in the Māori population, there was no significant correlation observed between 
the mean adipocyte sizes in all the adipose depots, which was seen in the NZ/European 
population. The only significant positive correlation observed between adipocyte size in Māori, 
was between PAT and EAT mean adipocyte size (p=0.021 r=0.57, figure 3.6A). Additionally, 
there was a significant positive correlation observed between BMI and AAT mean adipocyte 
size (p=0.002 r=0.74). 
Figure 3.6 Pearson r correlation matrix heat map graph demonstrating correlations between various patient 
variables in Māori (A) and Pacific (B) populations 
Values shown are r values demonstrating the degree of correlation between 2 variables. The closer to 1, the stronger the 
variable. Blue squares denote a positive correlation while red squares denote a negative correlation. # = p<0.05, * = 
p<0.005. A: Significant positive correlation observed between EAT and PAT mean adipocyte size (p=0.021 r=0.57) 
and between BMI and AAT mean adipocyte size (p=0.002 r=0.74) n=16. B: Significant positive correlation between 
SAT and AAT mean adipocyte size (p=0.022 r=0.88) as well as EAT and AAT mean adipocyte size (p=0.04 r=0.83). 
Significant negative correlation seen between age and SAT and AAT mean adipocyte size (SAT: p=0.003 r=-0.95, 
AAT: p=0.05 r=-0.81). BMI vs. SAT showed a significant positive correlation (p=0.02 r=0.88) while BMI and age 
showed a significant negative correlation (p=0.017 r=-0.89) n=6. 
A: B: 
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3.5.3 Correlation between adipocyte size and 
anthropomorphic/demographic variables in Pacific population 
Along with a significant positive correlation between SAT and AAT mean adipocyte size 
(p=0.022 r=0.88) and EAT and AAT mean adipocyte size (p=0.04 r=0.83), the Pacific 
population demonstrated some very interesting significant negative correlations (figure 3.6B). 
Contrary to the findings in the NZ/European population, in the Pacific population there was a 
significant negative correlation between age and AAT and SAT mean adipocyte sizes (SAT: 
p=0.003 r=-0.95, AAT: p=0.05 r=-0.81). Additionally, the Pacific population showed a 
significant positive correlation between BMI and SAT mean adipocyte size (p=0.02 r=0.88), 
but a significant negative correlation between BMI and age (p=0.017 r=-0.89). 
 
3.6 Left ventricular (LV) analysis 
For analysis of left ventricular images, I could only analyse n=27 because left ventricular 
images were not available from the previous cohort, and from my cohort, only 27 of the 48 
cases had left ventricular images available for analysis. For this analysis, the Māori and Pacific 
peoples were grouped together for statistical analysis as there was only n=3 Pacific patients 
with left ventricular data. This meant the total n=27 made up of NZ/European, Māori, Pacific 
and Indian people. NZ/European n=17 and Māori/Pacific n=9. 
 
3.7 BMI vs fibrosis and adipocyte infiltration 
In all populations, a ROUT (Q=1%) outlier test was performed and univariate linear regression 
analysis was performed. Surprisingly, it revealed no significant relationship between BMI and 
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3.8 Correlation matrixes of adipocyte, left ventricular and 
anthropomorphic/demographic variables 
A Pearson r correlation matrix was performed to identify any significant correlations between 
adipocyte size in SAT, AAT, PAT and EAT, age, sex, BMI, heart weight, percentage of 
adipocyte infiltration in the myocardium, percentage of fibrosis in the myocardium, number of 
adipocyte clusters in the myocardium, myocardium-adipocyte contact area and presence of 
Figure 3.8 Pearson r correlation matrix heat map graph demonstrating correlations between adipocyte, 
left ventricular and anthropomorphic/demographic data in the total population  
n=27  *= p<0.005, #= p<0.05. outliers removed using ROUT (Q1%) outlier test.  
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CVD (cardiovascular disease). The significant and/or notable correlations were then 
individually graphed and analysed for more specific statistical testing.  
 
3.8.1 Correlation between fibrosis and adipocyte size 
The total population correlation matrix revealed a significant positive correlation between the 
percentage of myocardial fibrosis and the mean adipocyte size in all adipose depots (SAT: 
p=0.003 r=0.58, AAT: p=0.016 r=0.49, PAT: p=0.001 r=0.64, and EAT: p=0.003 r=0.59) 
(figure 3.8). In the NZ/European population this was maintained between all except EAT 
adipocyte size (SAT p=0.012 r=0.59, AAT p=0.026 r=0.54, PAT p=0.005 r=0.65, EAT 
p=0.116 (figure 3.9A). Interestingly in the Māori/Pacific population, there was no significant 
correlation with any adipocyte sizes (figure 3.9B). 
  
Figure 3.9 Pearson r correlation matrix heat map graph demonstrating correlations between left ventricular 
and anthropomorphic/demographic variables in the NZ/European and Māori/Pacific populations 




3.8.2 Correlation between the percentage of adipocyte infiltration and 
EAT adipocyte size 
Another significant positive correlation in the total population was between the percentage of 
adipocyte infiltration in the myocardium and mean EAT adipocyte size (p=0.04, r=0.43) (figure 
3.8). Interestingly this was not shown in the NZ/European population but did appear in the 
Māori/Pacific (p=0.023 r=0.74) (figure 3.9).  
 
3.8.3 Correlations between age and cardiovascular disease, and number of 
adipocyte clusters and myocardium-adipocyte contact area 
There were two significant positive correlations which were evident in all populations. Firstly 
the significant correlation between CVD prevalence and age (total population p<0.0001, 
r=0.56) (NZ/European p=0.0001 r=0.53) (Māori/Pacific p=0.015 r=0.68) (figures 3.8-3.9). 
Secondly, the significant positive correlation between the number of adipocyte clusters in the 
myocardium compared with the myocardium-adipocyte contact area (total population 
p<0.0001, r=0.68) (NZ/European p=0.022 r=0.549) (Māori/Pacific p=0.002 r=0.88) (figures 
3.8-3.9). 
 
3.8.4 Correlation between BMI and heart weight 
The next finding in the total population was a significant positive correlation between BMI and 
heart weight (p<0.0001, r=0.5, figure 3.8), which was replicated in the NZ/European 
population (p<0.0001 r=0.626, figure 3.9A), however there was no correlation between these 
variables in the Māori/Pacific population (figure 3.9B).  
 
3.8.5 Correlation between adipocyte infiltration, fibrosis, number of 
adipocyte clusters and myocardium-adipocyte contact area 
The total population demonstrated a significant positive correlation between the percentage of 
adipocyte infiltration and the percentage of fibrosis in the myocardium (p=0.011, r=0.53), the 
number of adipocyte clusters (0.006, r=0.55) and myocardium-adipocyte contact area 
(p<0.0001, r=0.71) (figure 3.8). While there was a loss of the significant relationship between 
the percentage of adipocyte infiltration and fibrosis in the NZ/European population, this 
population still demonstrated a significant positive correlation between adipocyte infiltration 
compared to the number of adipocyte clusters (p=0.013 r=0.587) and the myocardium-
41 
adipocyte contact area (p<0.0001 r=0.895) (figure 3.9A). In the Māori/Pacific population 
however, none of these correlations were significant (figure 3.9B). 
 
3.8.6 Correlations with cardiovascular disease (CVD) 
Another significant positive correlation was observed between cardiovascular disease 
prevalence and the number of adipocyte clusters in the myocardium in the total population 
(p=0.025, r=0.43) (figure 3.8). Surprisingly, in the NZ/European population this was still 
significant but now a negative correlation (p<0.0001 r=-0.304)(figure 3.9A). Similarly to 
previous findings, these variables did not share a significant correlation in the Māori/Pacific 
population. Interestingly, in the total and Māori/Pacific populations there was no significant 
correlation between CVD prevalence, the percentage of fibrosis or adipocyte infiltration in the 
myocardium (figure 3.9B). However in the NZ/European population we see numerous 
significant correlations between CVD prevalence and left ventricular variables. For example, 
CVD prevalence showed a significant positive correlation with the percentage of fibrosis in the 
myocardium (p<0.0001 r=0.23), and with mean adipocyte size in all 4 adipose tissue depots 
(SAT: p=0.0001 r=0.29, AAT: p=0.0001 r=0.3, PAT: p<0.0001 r=0.17, EAT: p<0.0001 
r=0.53). Additionally in the NZ/European population, CVD prevalence showed a significant 
positive correlation with heart weight (p=0.0001 r=0.29), but surprisingly they showed a 
significant negative correlation to myocardium-adipocyte contact area (p<0.0001 r=-0.27) and 
the percentage of adipocyte infiltration into the myocardium (p<0.0001 r=-0.43).  
 
3.8.7 Correlation between heart weight and age 
Lastly, the NZ/European population showed a significant positive correlation between heart 
weight and age (p=0.024 r=0.42) (figure 3.9A). Surprisingly, none of the populations 
demonstrated a significant correlation between BMI and CVD prevalence in any of the 
populations. 
 
3.9 Correlation between fibrosis in the myocardium and SAT, 
AAT, PAT and EAT adipocyte size 
In the total population data, after a significant correlation was identified using the Pearson r 
correlation matrix, a ROUT (Q=1%) outlier test was performed which strengthened the 
significant relationship between mean adipocyte size in all visceral adipose tissue depots and 
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the percentage of fibrosis in the left ventricular myocardium (figure 3.10). Appendicular (AAT) 
mean adipocyte size demonstrated a highly significant relationship with the percentage of 
myocardial fibrosis (p=0.0012, r2=0.3840, figure 3.10B), as did pericardial (PAT) (p=0.0049, 
r2=0.2966, figure 3.10C) and epicardial (EAT) (p=0.0346, r2=0.18, figure 3.10D) mean 
adipocyte sizes. However subcutaneous (SAT) mean adipocyte size did not show a significant 
linear relationship with the percentage of left ventricular myocardial fibrosis (p=0.8589, figure 
3.10A). 
 
This same statistically significant relationship was also seen in the NZ/European population 
(SAT: p=0.032 r2=0.4730, AAT: p=0.0117, r2= 0.375, PAT: p=0.0006, r2= 0.5834, EAT: 
Figure 3.10 Univariate linear regression analysis of percentage of fibrosis in the myocardium vs. mean adipocyte 
area in subcutaneous (SAT), appendicular (AAT), pericardial (PAT) and epicardial (EAT) adipose tissues in the 
total population. 
A: no significant relationship between SAT adipocyte size and percentage of myocardial fibrosis p=0.8589 B: Linear 
relationship between AAT adipocyte size and myocardial fibrosis, p=0.0012, r2=0.3840 C: Linear relationship between 
PAT adipocyte size and myocardial fibrosis, p=0.0346, r2=0.18 D: Linear relationship between EAT adipocyte size and 
fibrosis, p=0.0049, r2=0.2966. Calculated using a ROUT (Q=1%) outlier test and univariate simple linear regression. 
AAT n=23, PAT and EAT n=24. 
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p=0.0015, r2=0.5263, figure 3.11A). However, this significant relationship did not exist for 
mean adipocyte size in any of the adipose tissue depots and percentage fibrosis in the Māori 
and Pacific population (figure 3.11B) (SAT: p=0.8254, AAT: p=0.2328, PAT: p=0.4864, EAT: 
p=0.2954). Additionally, still no significant relationship appeared in this population despite the 
application of a ROUT (Q=1%) outlier test. 
 
3.10 Correlation between percentage fat in the myocardium and 
mean epicardial adipocyte size: 
A univariate linear regression analysis revealed a significant linear relationship between EAT 
mean adipocyte size and the percentage of adipocytes in the left ventricular myocardium in the 
Māori/Pacific population (p=0.023, r2=0.5455) (figure 3.12). However, there was no significant 
relationship seen in the total nor NZ/European populations (p=0.6622, p=0.4122). Even when 
a ROUT (Q=1%) outlier test was performed and outliers were removed from the total and 
A: B: 
Figure 3.11 Multivariate linear regression analysis of the percentage of left ventricular myocardial fibrosis and 
mean adipocyte size in subcutaneous (SAT), appendicular (AAT), pericardial (PAT), and epicardial (EAT) 
adipose depots in the NZ/European and Māori/Pacific populations. 
A: NZ/European linear regression analysis performed with ROUT (Q=1%) outlier test, SAT p=0.032 r2=0.4730, AAT 
p=0.0117, r2= 0.375, PAT p=0.0006, r2= 0.5834, EAT p=0.0015, r2=0.5263. NZ/European n=16, Māori/Pacific n=9. 
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NZ/European populations, there was no relationship between EAT mean adipocyte size and 
the percentage of adipocytes in the left ventricular myocardium.  
 
3.10.1 Correlation between age and cardiovascular disease prevalence: 
A two-way ANOVA and post hoc Sidak’s multiple comparisons test revealed a significant 
difference between the age of individuals with cardiovascular disease (CVD) and without 
(figure 3.13). There was a significant relationship between CVD and no CVD in the total 
population (p=0.0003) and NZ/European populations (p=0.0213). However, there was no 
significant difference between CVD and no CVD in the Māori/Pacific population.  
 
Figure 3.12 Univariate linear regression analysis of adipocyte infiltration into the myocardium vs. mean 
epicardial adipocyte size in the total, NZ/European and Māori/Pacific populations. 
A significant relationship is seen between the percentage of adipocytes in the left ventricular myocardium and EAT 
mean adipocyte size in the Māori/Pacific population (p=0.023, r2=0.5455). No significant relationship was seen in 
NZ/European and total populations (p=0.4122, p=0.6622). Māori/Pacific n=12, NZ/European n=29, total n=48. 
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3.10.2 Correlation between BMI and heart weight: 
A univariate linear regression analysis revealed a significant correlation between BMI and 
heart weight in the total population (p=0.0003 r=0.2531, figure 3.14A). This same relationship 
was also shown in the NZ/European population (p=0.0003 r=0.3922, figure 3.14B) however 
there was no significant relationship between these variables in Māori/Pacific population 






Figure 3.13 Bar graph demonstrating average age of individuals with cardiovascular disease (CVD) and without 
(no CVD) in the total, NZ/European and Māori/Pacific populations. 
A significant relationship was observed between CVD and no CVD in the total population (p=0.0003) and between 
CVD and no CVD in the NZ/European population (p=0.0213). Total n=48, NZ/European n=28, Māori/Pacific n=12. *= 
p<0.005, #= p<0.05. Calculated using a two way ANOVA and post hoc Sidak’s multiple comparison test and values are 







Figure 3.14 Univariate linear regression analysis between BMI and heart weight in the total, NZ/European 
and Māori/Pacific populations 
A: the total population B: NZ/European and C: Māori/Pacific populations (red = Māori, brown = Pacific). 
Significant linear relationship was identified in the total population (p=0.0003, r2=0.2531), and the NZ/European 
population (p=0.0003, r2=0.3922). No significant relationship was identified in the Māori/Pacific population 








Chapter 4 | Ūpoko Tuatwhā  





The overarching aim of this study was to identify differences in the microscopic morphology 
of adipose tissue and left ventricular myocardium, between NZ/European, Māori and Pacific 
New Zealanders. Initial differences were brought to light in 2019 by Aitken-Buck et al., who 
observed that obesity-induced changes in microscopic epicardial adipocyte morphology, did 
not coincide with changes observed in visceral or subcutaneous adipocyte morphology 
(Aitken-Buck et al., 2019a). However, Aitken-Buck et al., did not investigate this relationship 
specifically in Māori and/or Pacific populations. Additionally, there was no research into how 
microscopic adipocyte morphology might relate to adipose infiltration into the myocardium. 
Therefore, my research aimed to extend these previously identified differences, while 
simultaneously widen the scope to also assess possible associations between changes in cardiac 
morphology, and individual anthropomorphic and demographic parameters in ethnically 
diverse New Zealand populations. My key findings were, that non-epicardial adipocytes 
undergo hypertrophy in response to increasing BMI in NZ/European and Māori individuals, 
but not in Pacific individuals. Secondly, I found a significant linear relationship between 
myocardial fibrosis and visceral adipocytes size in the total and NZ/European populations, 
however not in Māori/Pacific populations. Lastly, I observed that the degree of myocardial 
adipocyte infiltration, significantly correlated with EAT adipocyte size in Māori/Pacific but 
not NZ/European populations. These interesting novel findings, provide a platform for further 
research into differences in adipose tissue morphology and physiology between different ethnic 
groups in obesity. 
 
4.1 Differences between SAT, AAT, PAT and EAT adipocyte sizes 
Analysis of adipocyte size data from 4 anatomically distinct adipose tissue depots 
(subcutaneous, appendicular, pericardial, epicardial), revealed that in the total and 
NZ/European populations, pericardial and epicardial adipocytes were significantly smaller 
than subcutaneous and appendicular adipocytes (figure 3.1A-B). This finding is consistent with 
the well-established understanding, that adipocytes from subcutaneous adipose tissues are 
larger than adipocytes from visceral adipose depots (Liu et al., 2009). To illustrate this, 
abdominal subcutaneous adipocytes are observed to be 12%-30% larger than visceral 
adipocytes from omental, retroperitoneal and mesenteric regions (Reynisdottir et al., 1997; 
Tchernof et al., 2006; Liu et al., 2009). Again, in line with my findings, it has been shown that 
subcutaneous and visceral adipocytes are 20% and 10% larger than epicardial adipocytes 
respectively (Marchington et al., 1989; Eiras et al., 2010; Bambace et al., 2011). My research 
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also found no significant difference between pericardial and epicardial adipocyte size, nor 
subcutaneous and appendicular adipocyte size (figure 3.1). A significant difference in 
adipocyte size between pericardial and epicardial depots has previously been reported in a 
guinea pig model (Marchington & Pond, 1990). However more recently using methods similar 
to the histological analysis methods used in my study, it was found that pericardial and 
epicardial adipocyte sizes were not significantly different (Aitken-Buck et al., 2019a). Relating 
to SAT and AAT adipocytes in humans, no significant difference in adipocyte size was 
observed between abdominal subcutaneous and abdominal visceral adipocytes (Verboven et 
al., 2018). This is a curious finding, as the term “visceral adipose tissue” encompasses AAT, 
PAT and EAT, while subcutaneous (SAT) is its own category. This categorisation (on the basis 
of anatomical location), has previously informed that the 3 visceral adipose tissues might share 
greater characteristic similarities with each other, than with subcutaneous adipose tissue 
(Ibrahim, 2010). However, my findings suggest that proximal vs distal localisation in relation 
to the heart, might be a greater determinant of similarities in microscopic adipocyte 
morphology, than the simple classification of adipose tissue as visceral or subcutaneous. 
Overall, previous findings in conjunction with my own, are in accordance with the regional 
adipocyte distinction characterised by (Aitken-Buck et al., 2019a) whereby subcutaneous 
adipocytes hypertrophy prior to visceral.  
 
These findings have informed two new ideas to explain why epicardial and pericardial 
adipocytes are significantly smaller than their subcutaneous and appendicular counterparts. 
Firstly, the thoracic cavity where the pericardial and epicardial adipose tissues are located, is 
anatomically restricted by the surrounding ribcage anteriorly and laterally. Additionally, fascia 
and other organs which make up the thoracic cavity, such as the heart and lungs play a role in 
this physical restriction. Therefore, I hypothesise that physical restriction plays a role in 
restricting pericardial and epicardial adipocytes from undergoing excessive hypertrophy in 
conditions of energy surplus, while adipose tissues outside the thoracic can. By this same logic, 
subcutaneous adipose depots could easily undergo hypertrophic expansion due to the covering 
skin’s ability to stretch, which is seen in subcutaneous adipose tissue. My second idea, is that 
due to their location, the lipids/energy stored in these epicardial (and pericardial) adipocytes 
are constantly being utilised by the adjacent heart, which is in perpetual need of energy. This 
might mean that the visceral (pericardial and epicardial) adipocytes surrounding the heart, are 
unable to undergo excessive hypertrophy as they are constantly undergoing lipolysis. This 
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would be unlike adipocytes in adipose tissues distally (subcutaneous and appendicular), which 
could undergo excessive hypertrophy, as they are not in direct contact with organs that have 
such a constant high demand for energy. 
 
In Māori people, my research showed that pericardial and epicardial adipocytes were 
significantly smaller than subcutaneous but not appendicular adipocytes (figure 3.1C). This 
finding is in accordance with the previously established physiological role of subcutaneous 
adipocytes, as high propensity absorbers of excess circulating glycerol and free fatty acids 
(Cervantes et al., 2019). This proposes that initially, subcutaneous adipocytes are the principle 
absorbers of circulating free fatty acids, and only once they have reached their maximum 
hypertrophic state, do visceral adipocytes (such as appendicular adipocytes) then take over this 
role. This proposition of a hierarchy that determines which adipocytes absorb circulating free 
fatty acids, also supports the observable trend in my data for Māori, whereby adipocyte size 
decreases moving from subcutaneous to appendicular, and finally to epicardial and pericardial 
adipose tissues (p=0.0009) (figure 3.1C).  
 
Interestingly, the mean subcutaneous adipocyte size in Māori (6269µm2) was much larger in 
than non-Māori (NZ/Euro: 4648µm2, Pacific: 4754µm2, p=0.049), which may suggest that 
subcutaneous adipocytes in Māori, have a greater hypertrophic capacity than that of the same 
adipocytes in other ethnic groups. This might help explain the increased proportion of Māori 
with significant subcutaneous (particularly abdominal) adipose tissue deposition (Cervantes et 
al., 2019). Previously, an increase in this more visible (subcutaneous) adipose tissue, has been 
perceived as an indicator of overall health (Sjöström et al., 1995), however my data suggests 
that this might not be accurate in Māori. In Māori cases, a greater substantial increase in 
subcutaneous adipocyte size, might become visibly evident prior to any significant pathological 
increase in visceral adipocyte size. Nevertheless, the lack of significant difference in size 
between appendicular, pericardial and epicardial adipocytes in Māori people (compared to the 
significant difference between them in NZ/European) might indicate that these visceral adipose 
tissues are more closely linked, and demonstrate more similar morphology and remodelling 
characteristics in Māori, than they do in non-Māori. 
 
Lastly, in Pacific people, there was no significant difference between the adipocyte size in any 
of the 4 adipose tissue depots. However, this finding might not be a true reflection of the Pacific 
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population, due to a lack of statistical power (n=6). The Pacific people’s data displays a similar 
observable trend to the total and NZ/European populations (figure 3.1D), and to the best of my 
knowledge there has been no published evidence against regional adipocyte distinction in 
Pacific people.  
 
4.2 Adipocyte size vs BMI 
In the total and NZ/European population, my hypothesis was substantiated, and I was able to 
replicate the previous findings by Aitken-Buck et al., (which served as the foundation for this 
work). I observed that subcutaneous, appendicular and pericardial adipocyte size had a positive 
linear relationship with BMI, while epicardial adipocyte size did not (figures 3.2-3.3) (Aitken-
Buck et al., 2019a). This finding also corroborates the well-established model that 
subcutaneous and various visceral adipocytes undergo hypertrophy due to an increase in BMI 
(Tchoukalova et al., 2008). While my findings supplement the argument that epicardial adipose 
tissue morphology is distinct from other adipose tissue morphologies, this is an interesting 
observation as previous research regarding the relationship between epicardial adipocyte size 
and BMI has been conflicting. For example, Sons & Hoffmann observed a significant positive 
relationship between epicardial adipocyte size, and body weight in post mortem cases (Sons & 
Hoffmann, 1986). In addition, they demonstrated that individuals with an average BMI of 
30.1kg/m2 and 34.7kg/m2, demonstrated a 21% and 47% increase in epicardial adipocyte size 
respectively, when compared to those with an average BMI of 22.2kg/m2. In opposition, Eiras 
et al., found no correlation between BMI and epicardial adipocyte size (Eiras et al., 2010). It 
is important to note that while these studies are contradictory, they record similar adipocyte 
size profiles which my data is also in line with. Nevertheless, I am confident that in accordance 
with Aitken-Buck et al., (Aitken-Buck et al., 2019a) the lack of correlation between EAT 
adipocyte size and BMI in my results is accurate. This is because the contradictory findings by 
Sons and Hoffmann, were comparing adipocyte size to body weight rather than BMI, 
additionally, in their data, significance was found only in some epicardial adipocytes, not all.  
 
This difference in BMI association between pericardial and epicardial adipocytes in my results, 
is particularly interesting when observed in conjunction with my previous findings, showing 
pericardial and epicardial mean adipocyte sizes were not significantly different. Due to the 
close anatomical location of pericardial and epicardial adipose tissues, they are commonly 
considered similar, however the differences in BMI associations between these two tissues 
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highlights their uniqueness. It is important to remember that epicardial and pericardial adipose 
tissues develop from different embryonic origins, and have varying relationships with their 
surrounding tissues (Wong et al., 2017). The pericardium creates a fascial boundary to encase 
EAT within the pericardial cavity, while excluding PAT. This anatomical distinction means 
the two tissues have different blood supplies, and no paracrine and vasocrine signalling 
between them, characteristics which inform each tissue’s unique physiological role (Nagy et 
al., 2017). Additionally, the unique location of EAT within the pericardium, might suggest a 
difference in local chemokines acting on EAT adipocytes compared to systemic chemokines 
acting on other distal adipose tissues, which are not protected by an outer layer of pericardial 
fascia. I theorize that fascia (pericardium) protecting EAT, enables EAT adipocytes to be 
partially protected from any possible remodelling and inflammation that more distal adipocytes 
might be exposed to. Thus, enabling EAT adipocytes to fulfil their essential role providing 
efficient fatty acid utilization for cardiac tissue. My findings regarding the BMI associations 
of epicardial and pericardial adipocytes, overall highlight the differences between the cardiac 
adipose tissues, and add to the evidence supporting the diversity in their physiological 
functions.  
 
Contrary to my hypothesis, the significant association between BMI and subcutaneous, 
appendicular and pericardial adipocytes, along with a lack of association between BMI and 
epicardial adipocyte size, was also found in the Māori/Pacific population. However, the Pacific 
population only demonstrated a significant relationship between subcutaneous adipocyte size 
and BMI. This might suggest that in Pacific populations, the subcutaneous adipocytes undergo 
hypertrophy in relation to an increasing BMI, while visceral adipocytes might not undergo 
hypertrophy to the same extent. This theory is also strengthened by the previously mentioned, 
well established idea that subcutaneous adipocytes are the first to take up excess circulating 
free fatty acids, and only once the subcutaneous hypertrophic capacity has been reached, do 
the visceral adipocytes take over this role (Cervantes et al., 2019). This highlights again, (as 
mentioned in Māori people above) that the visual measure of obesity for Pacific people (seen 
as an increase in subcutaneous adipose tissue) might not be an accurate representation of their 
visceral adipose tissue morphology. Therefore, in the Pacific population, BMI might not be an 
accurate measure of visceral obesity and cardiovascular disease risk. A lack of adipocyte 
hypertrophy in relation to increased BMI, has previously been linked with more severe 
manifestations of metabolic disease, when compared to a BMI increase with adipocyte 
53 
hypertrophy (Johannsen et al., 2014). Therefore, the lack of adipocyte hypertrophy in relation 
to increasing BMI observed in the Pacific population, might provide some insight as to why 
Pacific people are significantly more likely to suffer from metabolic disease than the general 
New Zealand population (Zealand, 2013). However, as previously mentioned, this lack of 
relationship might not be a true reflection of the physiology of Pacific people, but rather a lack 
of statistical power in the data (n=6).  
 
4.3 Correlation between adipocyte size and 
anthropomorphic/demographic variables 
In the total and NZ/European population correlation matrixes, a correlation between all mean 
adipocyte sizes was observed (figure 3.5). This suggests that an increase in adipocyte size in 
each depot, is somewhat proportional to a similar increase in adipocyte size in other depots 
throughout the body. This finding is in contrast with the previous rationale regarding 
differential adipocyte hypertrophy, whereby SAT adipocytes take up excess circulating fatty 
acids initially, before reaching their hypertrophic capacity, at which point visceral adipocytes 
take over this role. The significant correlation between mean EAT adipocyte size compared to 
the 3 other depots is particularly interesting considering thus far my results have highlighted 
the differences between EAT and other adipose tissues. A strong correlation here suggests that 
the unique anatomical location of EAT might not impose a significant effect on the 
physiological response and/or remodelling of EAT, when compared to other adipose tissues. 
This assumption of seemingly uniform remodelling across adipocytes, is contradictory to 
previous work by Marchington et al., who showed that isolated EAT, demonstrated a greater 
than 2x increase in lipogenic and lipolytic activity, compared to other visceral adipose tissues 
(Marchington et al., 1989). Overall these varying correlations, and somewhat conflicting 
results, highlight both the unique physiology, and the need for further research into EAT and 
its diverse functions. 
 
Intriguingly, a positive correlation between all mean adipocyte sizes was not seen in Māori nor 
Pacific populations (figure 3.6). This informs a different idea regarding the functional interplay 
between adipocyte depots in different anatomical locations, in the Māori and Pacific 
populations. That is to corroborate the previously discussed theory that in Māori and Pacific 
people, in conditions of excess circulating fatty acids, subcutaneous adipocytes undergo 
substantial hypertrophy first, before visceral adipocytes begin to undergo hypertrophy. This 
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characterises a differential degree of hypertrophy between various anatomically distinct 
adipose tissues, which is seen in the incongruence between adipocyte size increase in Māori 
and Pacific populations. In saying this, there was a significant correlation between EAT and 
PAT adipocyte size in Māori people, which substantiates the relationship between these two 
cardiac-related adipose tissues seen above (figure 3.1). Adding to the aforementioned results, 
in the Pacific population a significant correlation was observed between SAT and AAT mean 
adipocyte size (figure 3.6B). However intriguingly there was also a significant positive 
correlation between EAT and AAT mean adipocyte size. While this could be a representation 
of the similarities between visceral adipose tissue morphology in Pacific people, with n=6 for 
this population, this is speculation and more power is needed to substantiate these statements. 
 
In the total population, a significant positive correlation was observed between age, and PAT 
and EAT mean adipocyte size (figure 3.5A). While we have previously seen that BMI does not 
associate with EAT adipocyte size, perhaps age could provide an alternative indicator of the 
mean adipocyte size in adipose tissues surrounding the heart (pericardial and epicardial). A 
positive relationship between age and adipose tissue thickness, is well established in the field, 
and many studies show that age significantly correlates with an increase in visceral adipose 
tissue volume, relative to subcutaneous (Tchernof & Després, 2013). While there has not been 
extensive enquiry into changes in adipocyte size with age, my data suggests a similar 
relationship to that seen between age and adipose tissue thickness may be present. In the 
NZ/European population, this relationship between age and mean adipocyte size was conserved 
for PAT and AAT adipose tissues. This is again consistent with the known literature (Tchernof 
& Després, 2013), and although the significant correlation of age and EAT adipocyte size was 
lost, the p value for this correlation was 0.055, therefore with greater statistical power, this 
correlation might become significant. In concurrence with my hypothesis, my previous linear 
regression models of adipocyte size vs BMI (figures 3.2, 3.3, 3.4), and the aforementioned 
literature (Tchoukalova et al., 2008; Aitken-Buck et al., 2019a), the total population 
demonstrated a significant correlation between BMI and SAT and AAT adipocyte size (figure 
3.5A). 
 
To address the aims of my research, it was important to keep the Māori and Pacific populations 
separate for analysis, in order to identify any ethnic differences in adipocyte morphology. 
However, the low n-value (n=6) in the Pacific population precludes further discussion of the 
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Pacific people’s correlations separately in the context of physiological differences between 
ethnic groups.  
 
4.4 Left Ventricular (LV) analysis: 
The left ventricle was chosen for analysis rather than the left atria, or right ventricle or atria, 
because the left ventricle plays the most significant role in pumping blood to the systemic 
circulation. Therefore, any observed changes in left ventricular histology that might affect 
contractility of the heart, would be likely to have a greater impact on cardiac health in that 
individual, than similar changes seen in the other chambers. Contrary to my hypothesis, I found 
no significant relationship between BMI and the percentage of fibrosis or adipocyte infiltration 
in the left ventricular myocardium (figure 3.7). This finding does not seem to be consistent 
with previously well-established knowledge, which implicates BMI and hyperplastic adipose 
tissue remodelling as a significant risk factor in the development of heart disease, through 
excess myocardial fibrosis and myocardial adipocyte infiltration (Scaglione et al., 1992; 
Pascual et al., 2003; Tandon et al., 2018). However, to explain this perceived discrepancy, we 
must understand the physiology of the area. Firstly, the fibrosis and adipocyte infiltration data 
in my study is collected from the left ventricle. The left ventricle the highest pressure chamber, 
as it is responsible for pumping blood throughout the body to the distal systemic circulation. 
The fact that the left ventricle must produce the highest pressure of all the chambers of the 
heart, means it also has the highest energy demand. Therefore, I theorise that in conditions of 
elevated BMI (and commonly associated high levels of circulating free fatty acids), if 
adipocytes were to infiltrate into the left ventricular myocardium, they would rapidly undergo 
lipolysis for utilisation of energy rich lipids. In other chambers of the heart, which have a lesser 
energy demand, adipocytes would not so rapidly be utilised for energy, and therefore 
adipocytes may persist within the myocardial tissue. Recent findings by Miles et al. (Miles et 
al., 2020) support this idea, showing that in post-mortem heart sections, the right ventricle 
displayed a significantly greater proportion of fat and collagen (the main constituent of fibrosis) 
than the left ventricle. This idea of rapid adipocyte utilisation within the myocardium, is backed 
up by various observations during my analysis of left ventricular histology images. The most 
significant being that adipocytes within the myocardium that were surrounded by an area of 
fibrosis, were considerably larger than adipocytes that were surrounded by cardiomyocytes 
(appendix figure 1.4). This suggests that adipocytes embedded between contractile, energy 
hungry cardiomyocytes, seem to hypertrophy to a lesser extent than those surrounded by 
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fibrosis. Possibly because the fatty acids within myocyte locked adipocytes, are being utilised 
at a faster rate compared to the utilisation of fatty acids from adipocytes surrounded by fibrosis.  
 
Alternatively, the lack of correlation between BMI, adipocyte infiltration and myocardial 
fibrosis might suggest that BMI is not be the best measure of risk for heart disease, or the best 
indicator of an individual’s cardiac health. Previously, obesity (measured using BMI) has been 
an important diagnostic tool in assessing an individual’s risk of developing cardiovascular 
disease (Wild & Byrne, 2006). However, my findings highlight that BMI might not be the most 
accurate tool, and it might be time to realise more effective diagnostic markers. 
 
4.5 Correlations between left ventricular morphology and 
anthropomorphic/demographic variables  
In the total and divided study populations, a significant positive correlation was observed 
between the number of adipocyte clusters in the myocardium, and the myocardium-adipocyte 
contact area (figure 3.8, 3.9). This is not a surprise, as it is expected that the number of adipose 
depots within the myocardium, would have a direct relationship to the amount of contact area 
that the adipocytes have with the myocardium. As previously discussed, adipocytes are 
metabolically active, play a role in cell signalling, and secrete adipokines which have an impact 
on adjacent tissues (Nagy et al., 2017). The myocardium-adipocyte contact area was chosen 
for analysis because it was hypothesised that an increase in contact area between the adipocytes 
and myocardium, would result in the secreted adipokines from adipocytes, having a greater 
impact on the myocardium and possibly increasing the level of myocardial fibrosis. 
Unfortunately, myocardium-adipocyte contact area did not associate with myocardial fibrosis 
for any of the populations (figures 3.8-3.9), and while it was an interesting variable to asses, it 
seems that the extent of contact between adipocytes and myocardium, relates only to the 
number of adipocyte clusters in the myocardium, and the percentage of adipocyte infiltration 
(figures 3.8, 3.9).  
 
Following on from this, the total population demonstrated a significant positive correlation 
between the percentage of adipocyte infiltration and the percentage of myocardial fibrosis. This 
is an expected result, as both variables are well established to be linked manifestations of 
cardiac dysfunction and heart disease (Mahajan et al., 2015). Additionally it has been shown 
that the pathological expansion of adipocytes (such as their expansion and migration into 
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adjacent myocardium) prompts inflammation and extensive myocardial fibrosis (Sun et al., 
2011). This is the effect of previously mentioned adipokines, for example interleukin 6, 
monocyte chemotactic protein 1 and granulocyte colony stimulating factor, which recruit 
inflammatory cells and fibroblasts to the tissue site, resulting in fibrosis in that tissue (Skurk et 
al., 2007). This correlation between adipocyte infiltration, pro-inflammatory signalling, and 
myocardial fibrosis, is further corroborated by my observations, that areas of fibrosis in left 
ventricular histology images, were densely concentrated around blood vessels (appendix figure 
1.5). This suggests that inflammatory cells and fibroblasts are being recruited to the site through 
the bloodstream, and migrate through the endothelium to cause myocardial fibrosis. My 
observed correlation between adipocyte infiltration and myocardial fibrosis is particularly 
intriguing when compared to the aforementioned lack of correlation between myocardium-
adipocyte contact area and fibrosis. It seems logical that an increase in myocardial adipocyte 
infiltration would correlate with a comparable increase in myocardium-adipocyte contact area, 
however due to the shape of adipocytes and their clusters, this is not the case. As they are 
spherical, an increase in internal area does not always correlate to a comparable increase in 
circumference. This suggests another idea whereby it is not only the myocardium in direct 
contact with adipocytes which is effected by released adipokines. But rather, adipokines are 
able to diffuse through areas of fibrosis and other adipocytes to effect a defined local area of 
tissue within the myocardium. This suggest a justification for the observed link between 
adipocyte infiltration and fibrosis but not between contact area and fibrosis. In spite of this, the 
relationship between adipocyte infiltration and fibrosis was not seen in the NZ/European nor 
Māori/Pacific populations separately. This could be due to underlying differences in 
physiology, however due to the overwhelming consensus linking adipokine signalling and 
fibrosis, and the fact that the p value is almost significant (p=0.077), it might reflect this 
analysis was slightly underpowered. 
 
A significant positive correlation between cardiovascular disease (CVD) prevalence and the 
number of adipocyte clusters in the myocardium, was also identified in the total population 
(figure 3.8). This is expected, as adipocyte infiltration has been shown to both disrupt electrical 
conduction throughout the heart, and alter chemical and metabolic signalling, which 
subsequently affects the contractility of cardiomyocytes (Greulich et al., 2011; Greulich et al., 
2012; Nalliah et al., 2020). Interestingly, this finding conflicted with the negative correlation 
observed between CVD and the number of adipocyte clusters in the myocardium, in the 
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NZ/European population. It also conflicts with the lack of any significant correlation between 
CVD, the number of adipocyte clusters, and adipocyte infiltration in the Māori/Pacific 
population (figure 3.9B). Additionally, in the NZ/European population, the CVD prevalence 
showed a significant negative correlation with both the percentage of adipocyte infiltration in 
the myocardium, and the myocardium-adipocyte contact area (figure 3.9A). This is very 
surprising, as it has been suggested that an increase in adipocytes within the myocardium is 
suggested to increase in the risk of developing CVD (Nalliah et al., 2020). However, for my 
statistical analysis, CVD was input as a bivariate data set. For a more accurate assessment of 
the correlation between CVD and other variables, it would be more appropriate to input CVD 
prevalence on a scale of increasing severity, rather than as bivariate data. 
 
Lastly in the total population, a strong positive correlation between adipocyte size in all adipose 
tissues (SAT, AAT, PAT, EAT), and CVD was observed. This was also the case in the 
NZ/European (excluding an association with EAT adipocyte size), but not in the Māori/Pacific 
populations. This provides a link to my previous findings relating adipocyte size to BMI, as 
previously seen, an increase in BMI significantly correlated with an increase in non-epicardial 
adipocyte size. Additionally it is known that obesity (measured as an increase in BMI) is a 
significant risk factor of developing cardiovascular disease (Hubert et al., 1983). Therefore, it 
might be suggested that an increase in obesity can correspond with an increase in adipocyte 
size, and subsequently lead to the development of CVD. Despite this, it is also interesting to 
note that my results showed no correlation between BMI and CVD prevalence. This highlights 
(as previously discussed) the possible inaccuracy of BMI as an obesity measure, and diagnostic 
tool in assessing an individual’s risk of developing cardiovascular disease. 
 
4.5.1 Correlation between myocardial fibrosis and adipocyte size 
In the total population, a significant linear relationship was observed between the percentage 
of fibrosis in the myocardium, and the mean adipocyte size in visceral adipose tissues (AAT, 
PAT, EAT) (figure 3.10). This is a noteworthy finding, which suggests that visceral adipose 
tissues have a more intimate relationship with cardiac tissue, than subcutaneous adipose tissues 
do. This intimate link between visceral adipocytes and the myocardium has been extensively 
characterised, specifically between EAT and myocardium, and has been shown to lead to 
arrhythmic susceptibility (Hatem & Sanders, 2014; Venteclef et al., 2015; Abe et al., 2018). 
Additional research has shown a similar link between pericardial and other visceral adipocyte 
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hypertrophy, and myocardial fibrosis (Wang et al., 2018). In addition, it was found that visceral 
adipocyte hypertrophy had an emerging role in intestinal and mesenteric diseases, and a well-
established role in the development of fatty liver disease (Schäffler et al., 2005; Bays et al., 
2008). This suggests that visceral adipocyte hypertrophy has a similar pathophysiological 
effect on other organs, not only the heart. The consensus is that a combination of local and 
systemic effects of visceral adipocyte hypertrophy, are responsible for the pathological impact 
on organs, which ultimately lead to their dysfunction and remodelling (Tandon et al., 2018). 
My findings indicate that subcutaneous adipocytes do not show this same relationship with 
myocardial fibrosis (figure 3.10A). This might be as they are located more distal to the heart, 
therefore they might play less of a role in vasocrine and paracrine signalling related to the heart, 
and subsequently have less of an effect on cardiac remodelling.  
 
The significant linear relationship between the percentage of myocardial fibrosis and adipocyte 
size observed in the total population, was observed in the NZ/European population (figure 
3.11A). Additionally, the NZ/European population showed an added significant correlation 
with subcutaneous adipocyte size and myocardial fibrosis. Interestingly, there was no 
relationship observed between myocardial fibrosis and adipocyte size in any depots in the 
Māori/Pacific group (figure 3.11B). Aside from the low number of cases in the Māori/Pacific 
group, the age of the cases in the Māori/Pacific population was on average, younger than those 
in the NZ/European population. By proxy, a case in NZ/European population would have had 
a greater number of years for possible cardiac remodelling and fibrosis to occur, in comparison 
to a Māori/Pacific case. Subsequently, the Māori/Pacific case would have had less years for a 
possible fibrotic phenotype to develop. This might provide an explanation for the lack of 
correlation between increased adipocyte size and myocardial fibrosis in the Māori/Pacific 
population.  
 
Interestingly, some recent studies indicate that compared to their age matched NZ/European 
counterparts, Māori cases present with less myocardial fibrosis (Wilsher et al., 2017). This 
might suggest that rather than an age-related explanation, there might instead be underlying 
genetic differences in the susceptibility of developing myocardial fibrosis, between these 
populations. This genetic underpinning might suggest that at a given BMI (or obese state), 
NZ/European cases could have a greater degree of cardiac fibrotic remodelling, than Māori or 
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Pacific cases. This would again highlight that BMI might be inappropriate as an indicator of 
cardiovascular disease risk in Māori and Pacific people.  
 
4.5.2 Correlation between adipocyte infiltration and EAT size 
In the total population, a significant positive correlation between the percentage of adipocyte 
infiltration into the myocardium and mean EAT adipocyte size was observed (figure 3.12). 
Conversely to other observable trends between populations, this relationship was conserved in 
the Māori/Pacific population, but not NZ/European. The previously discussed unique 
anatomical location of EAT within the pericardial cavity, directly adjacent to the myocardium, 
might explain these findings. As epicardial adipocytes hypertrophy, they create excessive 
paracrine signalling, which acts directly on the myocardium, and can promote adipogenesis 
(Hatem & Sanders, 2014). Recent research in relation to EAT thickness and adipocyte 
infiltration in atrial fibrillation pathology, has also suggested an intimate relationship between 
epicardial adipocyte hypertrophy, and myocardial fibrosis (Wong et al., 2017). It is surprising 
that this EAT adipocyte size/fibrosis relationship is not conserved in the NZ/European 
population, however this might suggest underlying ethnic differences in adipocyte-induced 
cardiac remodelling. Potential, ethnic differences in adipocyte-induced cardiac remodelling, 
might provide some explanation of the observed discrepancies between Māori and 
NZ/European cardiac disease prevalence. Overall my findings relating EAT adipocyte size and 
myocardial adipocyte infiltration, might suggest that EAT hypertrophy in Māori and Pacific 
cases could correlate with myocardial fibrosis. While a similar degree of EAT hypertrophy in 
NZ/European cases, might not correlate with myocardial fibrosis.  
 
4.5.3 Age vs CVD 
In both the total and NZ/European populations, a significant difference in age was observed 
between cases with, and without the presence of cardiovascular disease (CVD). This is not 
particularly surprising, as advancing age is well established as a risk factor for the development 
of CVD (Roth et al., 2015). An advanced age suggests more life years where an individual 
could possibly have been exposing their body to pathophysiological conditions. Additionally, 
age is known to correlate to an increase in overall body adiposity, which is also a risk factor 
for CVD (Tandon et al., 2018). Although there was no significant difference between the age 
of Māori and Pacific people with and without CVD, an observable trend of lower ages is noted, 
which requires more statistical power to be confirmed.  
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4.5.4 BMI vs heart weight 
In the total and NZ/European populations, a significant positive correlation was observed 
between BMI and heart weight, while no correlation was observed between these variables in 
the Māori/Pacific population (figure 3.14). An additional correlation between age and heart 
weight was observed in the NZ/European population only (figure 3.9A). BMI, age and heart 
weight are key variables which are commonly recorded during a routine post mortem 
examination, and a linearly increasing relationship between BMI and heart weight is well 
characterised (Smith, 1928; Hanzlick & Rydzewski, 1990). Meanwhile, the literature provides 
conflicting evidence regarding the correlation of age with heart weight (Smith, 1928; He et al., 
2009). An increase in heart weight has also been associated with many chronic cardiovascular 
diseases, such as hypertension and congestive heart failure (Reiner et al., 1961; Ishijima, 1990). 
This known association between heart disease and heart weight, means that often in the case 
of an unknown cause death, an increased heart weight will suggest the diagnosis of sudden 
cardiac death (Basso et al., 2008). The correlation between heart weight, and BMI or age in 
NZ/European cases seems to support this suggestion (figure 3.9A). However, the lack of 
congruency within the Māori and Pacific populations, suggests this might be an inaccurate 
assumption to make for Māori and Pacific post-mortem cases. This suggests that Māori and 
Pacific cases with ambiguous causes of death, might have been given an incorrect cause of 
death in the past. 
 
4.6 BMI as an obesity measure 
It has been brought to light that BMI might not be an accurate measure of overall body adiposity 
(McCarthy, 2006). While extreme examples of body builders with enormous muscle mass are 
a classic example of how BMI is not always accurate (Garrido-Chamorro et al., 2009), for 
many years, BMI has nevertheless been accepted as the most satisfactory, and most accessible 
measure of adult obesity (Bergman et al., 2011). While this may hold true for Caucasian 
Americans and Europeans, there is increasing evidence, that BMI is not an acceptable obesity 
measure in indigenous and diverse ethnic populations (Li & McDermott, 2010; Rahman & 
Berenson, 2010). Additionally, the BMI cut-offs for classification as underweight, overweight, 
and obese, are inconsistent between governing bodies. For example, the National Institute of 
Health in the USA classes a BMI of >30kg/m2 as obese, while for the World Health 
Organisation it is >35kg/m2. My research further emphasises the need for a more accurate and 
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universal measure of body adiposity, and subsequent cardiovascular disease risk. This is 
supported by my finding that in Māori and Pacific populations, no significant correlation 
between increased BMI and adipocyte hypertrophy was observed in the majority of the adipose 
depots (figure 3.6). This is despite the well-established notion, that in overweight and obese 
conditions (which theoretically should coincide with an increased BMI), adipocytes undergo 
hypertrophic remodelling (Sun et al., 2011). Recent research has indicated that EAT thickness 
measurements may be a more accurate predictor of whole body adiposity, and thus 
cardiovascular disease risk (Mahabadi et al., 2013; Pierdomenico et al., 2013a). However, 
further research in this area is needed to substantiate this claim, and as such, this will be 
discussed in “future directions”. 
 
4.7 Limitations 
The first limitation to this study is that ethnicity was self-identified, and not based on genetic 
information. Furthermore, in recent decades in New Zealand there has been an increase in 
people identifying proudly as Māori and Pacific (Zealand, 2013). Additionally, the low number 
of cases available for Māori and Pacific people meant that that within one ethnic group there 
may be varying genetic proportions of that ethnicity, and thus varying degrees of the impact of 
that ethnicity on certain variables. However, analysis of the subpopulation of cases for my 
study, already provided some interesting associations, which will be determined in more detail 
and with sufficient power once the whole cohort of cases of this ongoing study is available for 
analysis. Another limitation is that information regarding lifestyle factors were not made 
available, and it is known that lifestyle factors such as diet, exercise, socioeconomic position, 
and access to healthcare play a huge role in obesity and cardiovascular health (Chiavaroli et 
al., 2019). A limitation I encountered during statistical analysis, was several relatively low r2 
values, for example r2=0.1075 for the linear correlation between subcutaneous adipocyte size 
and BMI in the NZ/European population. While this is important to consider, it does not 
inherently devalue the significance of the relationship identified, and instead in my study it 
highlights the need for a larger pool of data and additional cases in the study to generate greater 
statistical power.  
 
4.8 Future directions and implications 
The study is ongoing as part of an 18 month study with HeartOtago and the University of 
Otago. Future patient information will include subsequent data of adipose tissue volume from 
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all of the four adipose depots used for thus study, and will be collected from whole body PMCT 
scans. This will enable the future analysis of EAT volume as a risk factor for cardiovascular 
disease, and allow assessment of associations between EAT volume and all our other 
morphological and anthropomorphic/demographic variables. By increasing the sample size and 
the variables available for analysis, this study will progress and provide critically valuable 
insight into more differences in Māori and Pacific physiology, and help to explain the 
disparities in Māori and Pacific health in New Zealand. Analysis of paediatric cases was out of 
the scope of this study, however as childhood obesity is growing in New Zealand (Chiavaroli 
et al., 2019), it is important to uncover possible associations seen in paediatric cases in the 
future. When addressing Māori and Pacific health, it is common for researchers to group these 
ethnicities into the same category for analysis, citing a lack of patient numbers pertaining to 
these populations as an excuse. In future research, it is pertinent that this excuse no longer be 
used. Currently Māori make up over 16% of the New Zealand population, and Pacific make up 
over 7% (Zealand, 2013). Together this means that Māori and Pacific make up almost a quarter 
of New Zealand’s population, thus the excuse of an insufficient number of patients identifying 
as these ethnicities, is unfounded and is only perpetuating the unconscious bias against Māori 
and Pacific people in research. 
 
4.8.1  Kaupapa Māori health initiatives 
 A principal aspect of this research was to determine the universality of adipocyte morphology 
and cardiovascular disease characteristics between ethnic groups. My research has highlighted 
that there are indeed ethnic differences in many morphological variables relating to 
cardiovascular disease, and obesity in New Zealand. Currently, in the clinic, all ethnicities are 
diagnosed and treated using the same standard protocols, my research combined with current 
epidemiological data makes the unsuitability of this approach blindingly clear. It is known that 
there are genetic differences between ethnic groups which predispose some to the development 
of certain disease (Goodarzi, 2018). However, too often this genetic underpinning is used as 
an excuse to justify and accept unequal disease statistics, rather than as a reason to investigate 
more targeted approaches. My research is a call to action, and highlights the necessary changes 
needed in the diagnosis and treatment of diverse populations of New Zealanders. I believe the 
answer lies not only in future research, but in the implementation of Kaupapa Māori health 
initiatives. Kaupapa Māori is “a Māori way”, and is a phrase that encompasses the connection 
to Māori principles, and an understanding of the importance of Māori culture, language and 
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autonomy, essentially it describes a “by Māori, for Māori” approach. Since the late ’90s, there 
have been Kaupapa Māori initiatives brought into healthcare in New Zealand, to address the 
crippling inequities between NZ/European and Māori health outcomes. These include 
initiatives in oral healthcare such as Te Whare Kaitiaki at the University of Otago dental school, 
and mental healthcare initiatives such as Manawanui Oranga Hinengaro, the Auckland based 
mental health Centre. These initiatives produce strong evidence showing they significantly 
decrease the burden of disease for Māori in these areas (Broughton, 2006). However, despite 
their efficacy, Kaupapa Māori healthcare initiatives, are still not easily accessible to all Māori, 
nor are they available in relation to all areas of healthcare. Over the past 20 years, there have 
been numerous calls for more Kaupapa Māori initiatives in all spaces, but particularly relating 
to cardiovascular disease (Bramley et al., 2004). However, as of yet there have been no 
significant changes in this space. Therefore, I believe a crucial aspect of future work relating 
to obesity and cardiovascular disease in diverse ethnic groups in New Zealand, must be focused 
on a Kaupapa Māori approach. 
  
Another vital aspect of research involving Māori is an understanding of Māori ideology 
(Tikanga Māori). Unlike the beliefs held by many non-Māori (Pākehā) New Zealanders, Māori 
people believe that their physical body is connected to their land (whenua), soul (wairua), 
ancestry (tapuna) and future lineage (kauhou). This sacred nature of the body and its connection 
to the past and future, elucidates to why Māori are less likely to participate in organ donation 
for transplant, or medical research (Lewis & Pickering, 2003), and illuminates why researchers 
often cite a lack of Māori/Pacific data, and participant numbers in research. However, this is 
not due to a lack of Māori people on a population level, but rather a disconnect in the values 
and beliefs put forth by Māori, compared to Pākehā New Zealanders. Adding to this disconnect 
is an unfortunate, well-founded distrust of Pākehā medical professionals, and the Pākehā 
focused health system. This distrust means that Māori are less likely to engage in Pākehā led 
medical research, further perpetuating the common misconception that there are insufficient 
numbers of Māori for research analysis (Barton, 2008). This was even evident in this study, for 
4 Māori cases from which I received anthropomorphic and demographic information, I did not 
get access to adipose or myocardial images. A recent podcast by RNZ (getting better – a year 
in the life of a Māori medical student), goes in-depth into the critical issues disadvantaging 
Māori in New Zealand healthcare, and further highlights the need for change. This podcast was 
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particularly focusing on the unconscious bias placed on Māori in the clinic, and the 
misalignment and lack of understanding between Pākehā doctors and Māori patients. 
These are major obstacles that need to be addressed for future research to progress, and bring 
meaningful change to the health of Māori and Pacific New Zealanders. As researchers, we must 
work harder to not only tick the box of Māori consultation in research, but work to develop a 
relationship with Māori, and include Māori throughout the research journey. In doing this, it 
will help forge a much-needed mutualistic relationship between Māori and non-Māori in New 
Zealand healthcare, and facilitate the provision of equitable healthcare for all New Zealanders. 
 
4.9 Conclusions 
Overall I found, differences in adipocyte morphology and its associations with myocardial 
adipose infiltration and fibrosis, and anthropomorphic/demographic information of post-
mortem cases between Māori, Pacific people and NZ/Europeans. This finding accomplished 
the aims of my study and simultaneously supports and refutes my hypotheses. It supports that 
relationships between adipocyte sizes in obesity are not consistent for all ethnicities, however 
the relationships between myocardial adipocyte infiltration and fibrosis in different ethnicities 
were not what I hypothesised. This emphasises the complex physiological nature of obesity 
and heart disease in relation to ethnicity. In conclusion, these differences in adipocyte 
morphology between NZ populations, highlight possible physiological ethnic variances, which 
might associate with diverse risk factors and disease characteristics. More importantly, it 
should trigger discussions on the validity of current diagnostic and potential treatment 
strategies for cardiovascular disease and obesity in NZ populations. 
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1.1 Table of full case details 
Table 1 Full demographic, anthropomorphic, adipose and left ventricular data from 101 cases used for statistical analysis, 10 of which were excluded from analysis 
due to ineligibility to participate because certain post mortem characteristics for example age (below 18 years). BMI (body mass index)  
Case 
Number  




























% fat  
 Left 
ventricular 





                              
1  
M  NZ/European  48                            
27.44  
                                               
4,989  
                                                             
8,261  
                 
2,586  
                                         
2,563  
      
                              
2  
M  NZ/European  56                            
35.51  
                                               
6,373  
                                                             
6,861  
                 
4,222  
                                         
2,478  
      
                              
3  
M  NZ/European  58                            
27.47  
                                               
6,157  
                                                             
3,687  
                 
2,037  
                                         
2,515  
      
                              
4  
F  Pacific Islander  57                            
27.89  
                                               
4,239  
                                                             
3,215  
                 
3,454  
                                         
1,810  
      
                              
5  
F  NZ/European  43                            
21.97  
                                               
2,821  
                                                             
1,769  
                 
1,864  
                                         
2,687  
      
                              
6  
M  Indian  69                            
23.89  
                                               
5,062  
                                                             
6,048  
                 
3,384  
                                         
3,633  
      
                              
7  
M  NZ/European  68                            
22.41  
                                               
2,855  
                                                             
2,290  
                 
1,567  
                                         
2,457  
      
                              
8  
M  NZ/European  76                            
21.74  
                                               
2,710  
                                                             
3,047  
                 
2,476  
                                         
2,767  
      
                              
9  
M  Māori  59                            
34.15  
                                               
2,867  
                                                             
5,225  
                 
3,358  
                                         
3,725  
      
                            
10  
M  Māori  66                            
25.16  
                                               
3,488  
                                                             
2,935  
                 
2,092  
                                         
2,046  
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11  
F  Indian  75                            
18.99  
                                               
2,936  
                                                             
3,338  
                 
1,907  
                                         
3,464  
      
                            
12  
M  NZ/European  71                            
27.13  
                                               
5,139  
                                                             
4,855  
                 
2,585  
                                         
2,632  
      
                            
13  
M  NZ/European  39                            
22.57  
                                               
4,659  
                                                             
3,997  
                 
1,747  
                                         
1,690  
      
                            
14  
M  NZ/European  41                            
23.26  
                                               
2,597  
                                                             
4,295  
                 
1,844  
                                         
2,292  
      
                            
15  
F  NZ/European  63                            
31.59  
                                               
6,214  
                                                             
4,309  
                 
2,760  
                                         
3,533  
      
                            
16  
F  Pacific Islander  49                            
31.41  
                                               
3,940  
                                                             
5,579  
                 
2,084  
                                         
2,076  
      
                            
17  
M  NZ/European  28                            
20.11  
                                               
3,276  
                                                             
1,882  
                 
1,053  
                                         
1,639  
      
                            
18  
M  Indian  48                            
27.78  
                                               
5,980  
                                                             
8,111  
                 
2,783  
                                         
2,432  
      
                            
19  
M  Māori  43                            
30.76  
                                               
3,896  
                                                             
4,139  
                 
2,398  
                                         
1,686  
      
                            
20  
F  Asian  62                            
29.64  
                                               
4,786  
                                                             
4,147  
                 
2,268  
                                         
2,327  
      
                            
21  
M  NZ/European  25                            
19.05  
                                               
1,525  
                                                             
1,354  
                 
1,290  
                                         
1,409  
      
                            
23  
F  NZ/European  48                            
24.34  
                                               
2,618  
                                                             
3,225  
                 
1,305  
                                         
2,666  
      
                            
22  
F  Māori  22                            
31.60  
                                               
4,676  
                                                             
5,427  
                 
1,748  
                                         
2,119  
      
                            
24  
M  NZ/European  58                            
26.78  
                                               
4,852  
                                                             
6,044  
                 
3,599  
                                         
3,210  
      
                            
25  
M  NZ/European  41                            
30.04  
                                               
6,046  
                                                             
5,690  
                 
4,945  
                                         
2,390  
      
                            
26  
M  NZ/European  51                            
30.48  
                                               
3,393  
                                                             
5,706  
                 
3,159  
                                         
2,595  
      
                            
27  
F  Māori  43                            
29.76  
                                               
3,678  
                                                             
5,235  
                 
2,146  
                                         
2,837  
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28  
F  Pacific Islander  77                            
27.27  
                                               
1,953  
                                                             
3,344  
                 
3,129  
                                         
2,540  
      
                            
29  
F  NZ/European  27                            
24.44  
                                               
2,387  
                                                             
1,460  
                     
879  
                                     
1,862  
      
                            
30  
M  Asian  40                            
24.42  
                                               
5,611  
                                                             
7,188  
                 
2,150  
                                         
3,185  
      
                            
32  
M  NZ/European  48                            
23.46  
                                               
3,731  
                                                             
4,326  
                 
1,868  
                                         
2,740  
      
                            
33  
M  NZ/European  55                            
25.44  
                                               
4,008  
                                                             
2,434  
                 
1,923  
                                         
2,039  
      
                            
34  
M  NZ/European  73                            
28.71  
                                               
4,305  
                                                             
6,337  
                 
3,282  
                                         
3,064  
      
                            
35  
M  Māori  22                            
20.38  
                                               
2,476  
                                                             
2,176  
                 
1,558  
                                         
2,934  
      
                            
36  
F  Māori  41                            
35.19  
                                               
7,755  
                                                             
5,210  
                 
2,112  
                                         
2,194  
      
                            
37  
F  NZ/European  60                            
30.74  
                                               
6,149  
                                                             
5,556  
                 
2,545  
                                         
2,352  
      
                            
38  
M  NZ/European  37                            
25.43  
                                               
4,101  
                                                             
4,970  
                 
2,141  
                                         
2,185  
      
                            
39  
M  NZ/European  71                            
28.39  
                                               
4,140  
                                                             
6,266  
                 
3,558  
                                         
2,882  
      
                            
40  
M  NZ/European  57                            
32.93  
                                               
4,162  
                                                             
4,826  
                 
4,036  
                                         
2,344  
      
                            
41  
M  NZ/European  57                            
20.32  
                                               
2,936  
                                                             
3,279  
                 
1,865  
                                         
1,978  
      
                            
42  
F  NZ/European  68                            
24.74  
                                               
2,740  
                                                             
1,815  
                 
1,939  
                                         
1,921  
      
                     
43  
 F   NZ/European  75                            
30.09  
                                               
4,384  
                                                             
6,397  
                 
2,704  
                                         
2,853  
      
                     
44  
 F   NZ/European  76                            
28.44  
                                               
3,216  
                                                             
4,817  
                 
2,179  
                                         
2,203  
      
                     
45  
 M   NZ European  69                     
24.68  
                                         
3,003  
                         
2,934  
                
1,622  
                          
3,017  
Yes       
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46  
 F   NZ European  23                     
16.36  
                                         
1,457  
                         
1,892  
                
1,188  
                                               
2,374  
no     
                     
47  
 F   NZ European  73                     
28.04  
                                         
3,787  
                         
1,636  
                
2,266  
                          
3,577  
yes 2.04% 7.91%                19  
                     
48  
 M  NZ European  53                     
21.80  
                                         
3,269  
                         
1,262  
                
1,400  
                                               
1,399  
no 0.19% 1.33%                  5  
                     
49  
 M  Pacific Islander  56                     
28.40  
                                         
4,337  
                         
3,545  
                
1,956  
                          
3,108  
yes 2.55% 13.01%                52  
                     
50  
 F  NZ European  74                     
33.95  
                                         
3,576  
                         
6,551  
                
4,169  
                          
2,902  
yes 0.18% 9.30%                17  
                     
51  
 F  Indian  71                     
20.96  
                                         
3,539  
                         
1,919  
                
2,562  
                          
2,543  
yes       
                     
52  
 M  Māori  56                     
36.59  
                                         
4,143  
                         
8,780  
                
2,715  
                                               
3,225  
yes 0.34% 1.63%                  6  
                     
53  
 M  Pacific Islander  49                     
35.35  
                                         
4,833  
                         
2,794  
                
1,081  
                          
1,753  
yes 0.09% 0.07%                16  
                     
54  
 M  Indian  36                     
24.01  
                                         
5,348  
                         
3,902  
                
2,207  
                          
2,302  
no       
                     
55  
 M  NZ European  72                     
35.49  
                                         
5,354  
                         
5,058  
                
4,292  
                          
3,824  
yes 0.22% 4.59%                  6  
                     
56  
 F  NZ European  28                     
25.56  
                                         
4,696  
                         
3,643  
                
1,497  
                          
2,507  
no       
                     
57  
 M  Māori  41                     
22.60  
                                         
2,078  
                         
2,318  
                
1,205  
                          
1,870  
yes 0.64% 3.50%                47  
                     
58  
 Fe  NZ European  59                     
24.91  
                                         
6,109  
                         
7,653  
                
7,344  
                          
4,071  
no       
                     
60  
 M  NZ European  47                     
29.00  
                                         
3,507  
                         
7,678  
                
3,126  
                          
2,514  
yes       
                     
61  
 M  NZ European  57                     
23.82  
                                         
4,077  
                         
3,830  
                
2,333  
                          
2,300  
yes 0.24% 0.70%                21  
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62  
 M  NZ European  59                     
30.46  
                                         
8,472  
                         
8,288  
                
3,892  
                          
3,812  
yes 0.06% 8.84%                11  
                     
67  
 M  Māori  75                     
28.41  
                                         
4,216  
                         
4,265  
                
1,889  
                          
2,413  
yes       
                     
68  
 M  NZ European  72                     
30.09  
                                         
4,092  
                         
4,353  
                
2,361  
                          
3,038  
no 0.11% 1.60%                17  
                     
69  
 M  NZ European  77                     
25.56  
                                         
3,668  
                                              
4,671  
                                        
1,657  
                       
1,678  
yes 1.13% 0.95%                43  
                     
70  
 M  NZ European  48                     
29.41  
                                         
4,756  
                         
2,581  
                
2,638  
                                               
2,741  
yes 0.08% 0.06%                20  
                     
71  
 M  NZ European  60                     
25.22  
                                         
5,169  
                         
5,993  
                
1,847  
                          
1,543  
yes       
                     
72  
 M  Indian  55                     
29.71  
                                         
5,800  
                         
5,881  
                
2,512  
                          
2,108  
no       
                     
73  
 F   NZ European  82                     
21.76  
                                         
4,473  
                         
4,195  
                
3,870  
                          
1,658  
yes       
                     
74  
 F   NZ European  53                     
31.02  
                                         
4,984  
                         
2,634  
                
1,967  
                          
1,845  
yes       
                     
75  
 F   Māori  63                     
33.30  
                                         
5,968  
                         
3,731  
                
1,916  
                                               
1,974  
yes     
                     
76  
 M  NZ European  67                     
33.46  
                                         
3,878  
                         
9,057  
                
2,487  
                          
1,625  
yes 1.16% 2.41%                60  
                     
77  
 M  Asian  61                     
21.31  
                                         
5,887  
                         
4,546  
                
2,856  
                          
2,500  
yes       
                     
78  
 M  NZ European  72                     
24.57  
                                         
4,251  
                         
5,000  
                
3,743  
                          
1,816  
yes       
                     
79  
 M  NZ European  19                     
26.02  
                                         
7,145  
                         
4,785  
                
4,518  
                          
5,126  
no       
                     
83  
 M  Māori  38                     
28.69  
                                       
30,805  
                           
5,343  
                
1,526  
                          
1,637  
no 0.00% 4.11%                   -  
 81 
                     
84  
 M  Indian  61                     
23.88  
                                         
7,322  
                         
8,027  
                
4,223  
                          
4,254  
yes 2.10% 17.80%              164  
                     
85  
 M  NZ European  67                     
33.17  
                                         
2,195  
                         
8,332  
                
3,623  
                          
2,051  
no 0.85% 1.60%                10  
                     
86  
 M  Indian  38                     
24.06  
                                       
12,977  
                           
8,836  
                
6,584  
                          
4,933  
no       
                     
88  
 M  Asian  47                     
28.73  
                                         
6,890  
                         
6,821  
                
6,075  
                          
2,768  
yes       
                     
89  
 M  NZ European  73                     
24.69  
                                         
8,965  
                         
9,064  
                
6,531  
                          
5,835  
yes 2.82% 11.05%                30  
                     
90  
 M  NZ European  74                     
23.20  
                                         
9,871  
                       
15,076  
                  
5,890  
                        
8,107  
yes 0.30% 15.73%                10  
                     
91  
 M  Māori  52                     
38.30  
                                       
10,889  
                                          
3,315  
                       
2,951  
yes 0.37% 8.20%                24  
                     
92  
 M  NZ European  76                     
26.30  
                                         
9,577  
                       
12,373  
                  
6,683  
                        
4,804  
yes 0.62% 90.63%                12  
                     
93  
 M  NZ European  63                     
38.08  
                                       
10,233  
                         
12,147  
                
10,020  
                          
8,642  
yes       
                     
94  
 M  Māori  18                     
25.61  
                                         
5,604  
                         
4,769  
                
1,733  
                          
2,406  
no       
                     
95  
 M  NZ European  73                     
34.33  
                                         
4,859  
                         
5,393  
                
3,753  
                          
2,127  
yes 13.93% 13.05%                53  
                     
96  
 F  Māori  40                     
30.78  
                                         
4,182  
                         
2,946  
                
2,307  
                          
1,341  
yes 0.79% 3.56%                34  
                     
97  
 M  European  32                     
32.88  
                                         
5,034  
                         
3,158  
                
2,797  
                          
2,007  
no 0.35% 1.72%                10  
                     
98  
 M  Māori  51                     
32.72  
                                         
3,586  
                         
6,262  
                
2,044  
                          
2,413  
yes 1.73% 64.12%                23  
                     
99  
 M  NZ European                       
25.95  
                                         
4,030  
                         
4,565  
                
2,645  
                          
1,511  
no 8.86% 3.53%              284  
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100  
 F  Pacific Islander  25                     
40.26  
                                         
9,223  
                       
13,134  
                  
3,270  
                        
4,281  
no 4.66% 39.17%                22  
                   
101  
 M  NZ European  76                     
21.46  
                                         
7,974  
                         
5,157  
              
12,664  
                            
9,073  
no       
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1.2 Haematoxylin & Eosin staining protocol 
 
SOLUTIONS:  - Harris' Haematoxylin – see LPANPREAPR502 
 - 1% aqueous Eosin – see LPANPREAPR508 
 - Scott’s Tap Water Substitute – see LPANPREAPR510 
 
METHOD  1) Rinse slide briefly in water. 
 
   2) Stain in Harris Haematoxylin for 1 minute. 
 
   3) Rinse in water. 
 
   4) Blue in STWS. 
 
   5) Wash in water for 10 seconds.  
 
   6) Stain in 1% Eosin for 40 seconds. 
 
   7) Rinse in water. 
 
    8) Dehydrate, clear and mount. 
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1.3 Masson trichrome staining protocol 
Specimen preparation  
Fixation: 10% NBF  
Sections: 4um Paraffin  
 
METHOD  1) Dewax and hydrate.  
   2) Treat with Bouin’s fixative for 1 hour at 60°C, remove from oven 
        and allow  cooling for 10 minutes.  
   3) Wash in water until sections are clear.   
   Stop manual method here and place on Multistainer.  
   4) Stain in Weigert’s Haematoxylin solution for 10 minutes.  
   5) Wash in water.   
   6) Stain in Biebrich Scarlet - Acid Fuchsin solution for 10 minutes.  
   7) Rinse in water.  
   8) Differentiate in Phosphomolybidic /Phosphotungstic acid solution 
        for 15  minutes. Check to see that collagen is not red.  
   9) Rinse in water.  
   10) Counterstain in Aniline Blue solution for 6 minutes.  
   11) Rinse in water.  
   12) Differentiate in 1% Acetic acid for 3 minutes.  
   13) Rinse in water.  




1.4 Larger adipocyte size in areas of myocardial fibrosis
Appendix figure 1 Left ventricle histology image from case 49 demonstrating that adipocytes surrounded by 
myocardial fibrosis are  seemingly larger than those surrounded by myocardium. 
Black arrows (à) : large adipocytes embedded in myocardial fibrosis, Green arrows: small adipocytes in clusters 
within myocardium. Masson trichrome staining, red: cardiomyocytes, blue: fibrosis, white: adipocytes. 
500µm 
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1.5 Myocardial fibrosis concentrated around coronary blood vessels 
 
Appendix figure 2 Left ventricular histology image demonstrating the localisation of myocardial fibrosis around blood vessels 
A: case 100 left ventricle histology B: case 68 left ventricle histology. Masson trichrome staining, blue staining: fibrosis, red: cardiomyocytes, white: adipocytes. green 






1.6 Left ventricular image showing analysis of myocardium-




Appendix figure 3 Left ventricular image demonstrating analysis of adipocyte area and myocardium-
adipocyte contact area 
Case number 95 left ventricle histology. Mason trichrome stain red: cardiomyocytes, blue: fibrosis, white: 
adipocytes. Yellow line: outline area of adipocytes, green line: myocardium-adipocyte contact area. 
